US20050096707A1 - Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure - Google Patents

Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure Download PDF

Info

Publication number
US20050096707A1
US20050096707A1 US11/000,262 US26204A US2005096707A1 US 20050096707 A1 US20050096707 A1 US 20050096707A1 US 26204 A US26204 A US 26204A US 2005096707 A1 US2005096707 A1 US 2005096707A1
Authority
US
United States
Prior art keywords
electrodes
procedure
characteristic
sensor
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/000,262
Inventor
Michael Hill
Scott Jahns
James Keogh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Priority to US11/000,262 priority Critical patent/US20050096707A1/en
Publication of US20050096707A1 publication Critical patent/US20050096707A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114Cardiac control, e.g. by vagal stimulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/385Devices for inducing an abnormal cardiac function, e.g. fibrillation

Definitions

  • This invention relates to methods and systems for performing a medical procedure, especially procedures during which it is necessary to adjust the beating of the heart in order to allow the medical procedure to be performed on the heart or another organ. More particularly, this invention relates to methods and systems for monitoring and controlling one or more physiological and/or chemical parameters of a fluid such as blood or oxygen in the systemic and/or pulmonary circulatory systems during such a medical procedure.
  • a fluid such as blood or oxygen
  • CABG coronary artery bypass graph
  • CABG surgery also known as “heart bypass” surgery
  • CABG surgery generally entails using a graph to bypass the coronary obstruction.
  • the procedure is generally lengthy, traumatic and subject to patient risks.
  • a cardiopulmonary bypass (CPB) circuit also known as a “heart-lung machine”, to pump blood and oxygenate the blood so that the patients heart may be stopped during the surgery.
  • CPB cardiopulmonary bypass
  • CABG procedures are typically conducted on a stopped heart while the patient is on a (CPB) circuit.
  • a stopped heart and a CPB circuit enables a surgeon to work in a bloodless, still operative field.
  • problems associated with CABG procedures performed while on CPB including the initiation of a systemic inflammatory response due to interactions of blood elements with the artificial material surfaces of the CPB circuit and global myocardial ischemia due to cardioplegic cardiac arrest. For these reasons, avoiding the use of CPB or cardioplegic cardiac arrest may help minimize post-operative complications.
  • One method, as disclosed in U.S. Pat. No. 5,651,378 to Matheny and Taylor and in U.S. Pat. No. 5,913,876 to Taylor et al., for facilitating coronary bypass surgery on a beating heart and thereby avoid the use of CPB and cardioplegic cardiac arrest includes stimulating the vagal nerve electrically in order to temporarily stop or substantially reduce the beating of the heart. This may be followed by pacing the heart to start its beating.
  • Another method involves stopping the beating of the heart during coronary bypass surgery using electrical stimulation of the vagal nerve in combination with administration of drugs.
  • Another method as disclosed in U.S. Pat. No. 6,060,454 to Duhaylongsod, involves stopping the beating of the heart during coronary bypass surgery via the local delivery of drugs to the heart.
  • One aspect of the present invention provides a system for performing a medical procedure.
  • the system includes a sensor to sense a biological characteristic, a nerve stimulator to inhibit beating of a heart when the sensor senses the biological characteristic at a first value and a cardiac stimulator to stimulate beating of the heart when the sensor senses the biological characteristic at a second value.
  • the biological characteristic maybe a chemical characteristic of a tissue, a chemical characteristic of a fluid, a physical characteristic of a tissue, a physical characteristic of a fluid, a physiological characteristic of a tissue, and a physiological characteristic of a fluid.
  • the biological characteristic may be a characteristic of a body component such as the blood, blood, cardiac tissue, or a nerve.
  • the biological characteristic may be fluid flow, fluid pressure, mechanical pressure, temperature, electrical current, chemical concentration, presence of a protein, concentration of a protein, presence of a peptide, concentration of a peptide, a metabolic process, presence of a gas, concentration of a gas, presence of oxygen, concentration of oxygen, presence of carbon dioxide, concentration of carbon dioxide.
  • the system may also include drug delivery means such as a spray, a cream, an ointment, a medicament, a pill, a patch, a catheter, a cannula, a needle and syringe, a pump, and an iontophoretic drug delivery device to deliver at least one drug during the procedure.
  • drug delivery means such as a spray, a cream, an ointment, a medicament, a pill, a patch, a catheter, a cannula, a needle and syringe, a pump, and an iontophoretic drug delivery device to deliver at least one drug during the procedure.
  • the drug may be a beta-blocker, a cholinergic agent, a cholinesterase inhibitor, a calcium channel blocker, a sodium, channel blocker, a potassium channel agent, adenosine, an adenosine, receptor agonist, an adenosine deaminase inhibitor, dipyridamole, a monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, a bradykinin agent, a serotoninergic agonist, an antiarrythmic agent, a cardiac glycoside, a local anesthetic, atropine, a calcium solution, an agent that promotes heart rate, an agent that promotes heart contractions, dopamine, a catecholamine, an inotrope glucagon, a hormoone, forskolin, epinephrine, norepinephrine, thyroid hormone, a phosphodiesterase inhibitor prostacyclin, prostagiandin and a methyl
  • the nerve stimulator may stimulate a nerve such as a vagal nerve, a carotid sinus nerve, a fat pad.
  • the nerve stimulation may be stopped automatically when the sensor senses the biblogical characteristic at the second value.
  • Cardiac stimulation may begin automatically when the sensor senses the biological characteristic at the second value.
  • the nerve stimulator may be, for example, one or more electrodes, such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes,
  • the sensor may be an imaging system, an electrical sensor, a chemical sensor, an electromagnetic interference sensor, an electrochemical sensor, a pressure sensor, a sound wave sensor, a magnetic sensor, an ultraviolet sensor, a visible light sensor, an infrared sensor, a radiation sensor, a flow sensor, a temperature sensor, a gas sensor, an optical sensor, a pH sensor, a potentiometric sensor, a fluorescence sensor and a biosensor.
  • the cardiac stimulator may be, for example, one or more electrodes, such as cardiac stimulation electrodes, clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrode intravascular electrodes, balloon-type electrodes basket-type electrodes, tape-type electrodes, umbrella type electrodes, suction-type electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes.
  • electrodes such as cardiac stimulation electrodes, clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrode intravascular electrodes, balloon-type electrodes basket-type electrodes, tape-type electrodes, umbrella type electrodes, suction-type electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-
  • the system may also include a breathing regulator, which may control a respirator.
  • the breathing regulator may stimulate a phrenic nerve.
  • the breathing regulator may be, for example, one or more electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire-electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type
  • the medical procedure may be a surgical procedure, a non-surgical procedures, a fluoroscopic procedure, a cardiac procedure, a vascular procedure, a neurosurgical procedure, an electrophysiological procedure, a diagnostic procedure, a therapeutic procedure, an ablation procedure, an endovascular procedure, a liver procedure, a spleen procedure, a pulmonary procedure, an aneurysm repair, an imaging procedure, a CAT scan procedure, a MRI procedure, a pharmacological therapy, a drug delivery procedure, a biological delivery procedure, a genetic therapy, a cellular therapy, a cancer therapy, a radiation therapy, a transplantation procedure, a coronary angioplasty procedure, a stent delivery procedure, an atherectomy procedure, a procedure that requires precise control of cardiac motion, a procedure that requires precise control of bleeding, a non-invasive procedure, a minimally invasive procedure, an invasive procedure, a port-access procedure, an endoscopic procedure, a sternotomy procedure, a thoracotomy procedure
  • Another aspect of the present invention provides a method for performing a medical procedure.
  • a biological characteristic is sensed at a first value and a first signal related to the sensed biological characteristic is sent. Beating of a heart is inhibited in response to the first signal.
  • the medical procedure is then performed.
  • the biological characteristic is then sensed at a second value and a second signal related to the sensed biological characteristic at the second value is sent. Beating of the heart is stimulated in response to the second signal.
  • Beating of the heart may be inhibited automatically in response to the first signal. Beating of the heart may be stimulated automatically in response to the second signal. At last one drug may be delivered during the medical procedure. A nerve may be stimulated to inhibit beating of the heart. Breathing may be stopped while beating of the heart is inhibited. Breathing may be stopped automatically.
  • the biological characteristic may be a characteristic of blood, a characteristic of cardiac tissue, a characteristic of a nerve, a fluid flow characteristic, a pressure characteristic, a temperature characteristic, an electrical characteristic, a chemical concentration, a presence of a protein, a concentration of a protein, a presence of a peptide, a component of a metabolic process, a presence of a gas, a concentration of a gas, a presence of oxygen, a concentration of oxygen, a presence of carbon dioxide, a concentration of carbon dioxide, a chemical characteristic, a physical characteristic, and a physiological characteristic.
  • the device includes a processor, a sensor to sense a biological characteristic and at least one nerve stimulation electrode.
  • the processor receives a signal from the sensor and adjusts output from the nerve stimulation electrode in response to the signal.
  • the sensor may be an imaging system, an electrical sensor, a chemical sensor, an electromagnetic interference sensor, an electrochemical sensor, a pressure sensor, a sound wave sensor, a magnetic sensor, an ultraviolet sensor, a visible light sensor, an infrared sensor, a radiation sensor, a flow sensor, a temperature sensor, a gas sensor, an optical sensor, a pH sensor, a potentiometric sensor, a fluorescence sensor and a biosensor.
  • the nerve stimulation electrode may be one or more electrodes, such as endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • electrodes such as endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • the device may also include a cardiac stimulation electrode to stimulate beating of the heart.
  • the processor receives a signal from the sensor and adjusts output from the cardiac stimulation electrode in response to the signal.
  • the cardiac electrode may be, for example, one or more electrodes such as clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrodes, intravascular electrodes, balloon-type electrodes, basket-type electrodes, tape-type electrodes, umbrella-type electrodes, suction-type electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes.
  • electrodes such as clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrodes, intravascular electrodes, balloon-type electrodes, basket-type electrodes, tape-type electrodes, umbrella-type electrodes, suction
  • the device may also include a breathing regulation electrode for controlling breathing.
  • the processor adjusts the output from the breathing regulation electrode in response to the signal.
  • the breathing regulation electrode may be, for example, one or more electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes; basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes; clip electrodes, needle electrodes and probe electrodes.
  • electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes; basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type electrodes,
  • the device may also include a drug pump for delivering at least one drug.
  • the processor adjusts the output of the drug.
  • the drug may be, for example, a beta-blocker, a cholinergic agent, a cholinesterase inhibitor, a calcium channel blocker, a sodium channel-blocker, a potassium channel agent, adenosine, an adenosine receptor agonist, an adenosine deamrinase inhibitor, dipyridamole, a monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, a bradykinin agent, a serotoninergic agonist, an antiarrythmic agent, a cardiac glycoside, a local anesthetic, atropine, a calcium solution, an agent that promotes heart rate, an, agent that promotes heart contractions, dopamine, catecholamine, an inotrope glucagon, a hormone, forskolin, epinephrine norepinep
  • FIG. 1 is a schematic view of one embodiment of a system for monitoring at least one chemical, physical or physiological characteristic during a medical procedure in accordance with the present invention
  • FIG. 2 is a schematic view of one embodiment of a medical device in accordance with the present invention.
  • FIG. 3 is a flow diagram of one embodiment of a method of performing a medical procedure in accordance with the present invention.
  • FIG. 4 is a timeline view of one embodiment of a system for monitoring at least one chemical, physical or physiological characteristic during a medical procedure in accordance with the present invention.
  • FIG. 1 shows a schematic view of one embodiment of a system for performing a medical procedure in accordance with the present invention at 100 .
  • System 100 comprises a sensor 5 , a nerve stimulator 10 , and a cardiac stimulator 20 .
  • System 100 may also feature a controller 30 and a breathing regulator 40 .
  • Sensor 5 may be any suitable blood gas sensor for measuring the concentration or saturation of a gas in the blood stream.
  • sensor 5 may be a sensor for measuring the concentration or saturation of oxygen or carbon dioxide in the blood.
  • sensor 5 may be any suitable sensor for measuring blood pressure or flow, for example a Doppler ultrasound sensor system, or a sensor for measuring hematocrit (HCT) levels.
  • HCT hematocrit
  • sensor 5 may be a biosensor, for example, comprising an Immobilized biocatalyst, enzyme, immunoglobulin, bacterial, mammalian or plant tissue, cell and/or subcellular fraction of a cell.
  • the tip of a biosensor may comprise a mitochondrial fraction of a cell, thereby providing the sensor with a specific biocatalytic activity.
  • Sensor 5 may be based on potentiometric technology or fiber optic technology.
  • the sensor may comprise a potentiometric or fiber optic transducer.
  • An optical sensor may be based on either an absorbance or fluorescence measurement and may include an UV, a visible or an IR light source.
  • Sensor 5 may be used to detect naturally detectable properties representative of one or more characteristics, e.g., chemical, physical or physiological, of a patients bodily tissues or fluids.
  • naturally detectable properties of patients bodily tissues or fluids may include pH, fluid, flow, electrical current, temperature pressure, components of metabolic processes, chemical concentrations, for example, the absence or presence of specific peptides, proteins, enzymes, gases, ions, etc.
  • Sensor 5 may include one or more imaging systems, camera systems operating in UV, visible, or IR range; electrical sensors; voltage sensors; current sensors; piezoelectric sensors; electromagnetic interference (EMI) sensors; photographic plates, polymer-metal sensors; charge-coupled devices (CCDs); photo diode arrays; chemical sensors, electrochemical sensors; pressure sensors, sound wave sensors; magnetic sensors; UV light sensors; visible light sensors; IR light sensors; radiation sensors; flow sensors; temperature sensors; or any other appropriate or suitable sensor. Sensor 5 may be a continuous, in-line monitoring system or it may be attached to an extracorporeal device.
  • EMI electromagnetic interference
  • CCDs charge-coupled devices
  • Sensor 5 may be a continuous, in-line monitoring system or it may be attached to an extracorporeal device.
  • sensor 5 may be a cerebral blood flow sensor, in which case, the sensor may be placed in any suitable manner for sensing cerebral blood flow.
  • sensor 5 may be inserted between the skull and the dura of the brain.
  • sensor 5 may be placed in the patients neck.
  • at least a portion of sensor 5 may be placed in an artery, such as the carotid artery.
  • artery such as the carotid artery.
  • sensor 5 may be placed in a vein, such as the jugular vein. This placement would allow measurement of blood as it flows from the brain.
  • a certain level of oxygen generally remains in the blood as it flows from the brain. This level may be established by measuring the patients oxygen prior to surgery. If blood measured by sensor 5 in the vein has oxygen below the established level, the brain is consuming all or most of the oxygen flowing to it and probably requires additional oxygen. Other suitable placements of sensor 5 may be possible. Sensor 5 may be used to alert a surgeon to changes in the patients circulatory, system.
  • System 100 may also include a nerve stimulator 10 .
  • the nerve stimulator 10 may be used to electrically manipulate cardiac rhythm by stimulating the vagus nerve. This vagal stimulation may produce asystole (slowing or stopping of the hearts beating.) Once this induced asystole is stopped, i.e. once the vagal stimulation is stopped, the heart may be allowed to return to its usual cardiac rhythm. Alternatively, the heart may be paced with an electrical pacing system, thereby maintaining a normal cardiaic output. Vagal stimulation, alone or in combination with electrical pacing, may be used selectively and intermittently to allow a surgeon to perform a medical procedure during intermittent periods of asystole.
  • vagal nerve stimulation can reduce the sinus rate, as well as prolong AV conduction time or if stimulation energies are high enough, induce AV node block.
  • Use of vagal nerve stimulation to treat supraventricular arrhythmias and angina pectoris is disclosed in the article “Vagal Tuning” by Bilgutay et al., Journal of Thoracic and Cardiovascular Surgery, Vol. 56, No. 1, July, 1968, pp. 71-82.
  • stimulation of the carotid sinus nerve produces a similar result, as disclosed in the article “Carotid Sinus Nerve Stimulation in the Treatment of Angina. Pectoris and Supraventricular Tachycardia” by Braunwald et al., published in California Medicine, Vol. 112, pp. 41-50, March, 1970.
  • the fat pads associated with both the AV node and the SA node may be stimulated by means of electrodes located in the right pulmonary artery.
  • the results obtained include-both a depression of the sinus rate and a prolongation of the AV conduction time in response to continuous stimulation at 2-80 Hz at up to 50 ma.
  • the SA node functions as the pacemaker.
  • Normal heart rhythm associated with the SA node is typically referred to as sinus rhythm.
  • the AV node generally takes over creating a heart rate of approximately 35 to 60 beats per minute.
  • Heart rhythm associated with the AV node is typically referred to as nodal rhythm.
  • a new seven slower pacemaker site may form at the junction of the AV node and the His bundle.
  • Heart rhythm associated with this junction is typically referred to as junctional, escape rhythm.
  • the Purkinje fibers in the His bundle or below may act as a pacemaker creating a heart rate of approximately 30 beats per minute.
  • Heart rhythm associated with the Purkinje fibers is typically referred to as idioventricular rhythm.
  • nerve stimulator 10 may be used to electrically manipulate cardiac rhythm by stimulating the carotid sinus nerve, the fat pad associated with the SA node, the fat pad associated with the AV node, the junction of the AV node and the His bundle and/or the Purkinje fibers.
  • nerve stimulator 10 is used alone or in combination with other heart rate inhibiting agents to temporarily stop or slow the beating heart, thereby eliminating or reducing heart motion and/or blood flow during a medical procedure.
  • the present invention may be used to eliminate or reduce motion in the anastomosis field during CABG Procedures such that a facilitated anastomosis procedure may be performed; safely and effectively.
  • the number of occasions that the vagal nerve may be stimulated depends on the type of medical procedure to be performed. Likewise, the type of medical procedure to be performed will dictate the duration of the individual electrical stimulations.
  • Nerve stimulator 10 may be powered by AC current, DC current or it may be battery powered either by a disposable or rechargeable battery. Nerve stimulator 10 may be configured to synchronize activation and deactivation of breathing regulator 40 with vagal stimulation, thereby minimizing or eliminating unwanted heart and chest motion associated with the patients breathing. Nerve stimulator 10 may comprise a surgeon controlled switch box. A switch may be incorporated in or on one of the surgeons instruments, such as surgical site retractor, or any other location easily and quickly accessed by the surgeon for regulation of the nerve stimulator by the surgeon. The switch may be, for example, a hand switch, a footswitch, or a voice-activated switch comprising voice-recognition technologies.
  • a visual and/or audible signal used to alert a surgeon to the completion or resumption of vagal nerve stimulation may be incorporated into nerve stimulator 10 .
  • a beeping tone or flashing light that increases in frequency as the nerve stimulation period should end or begin may be used.
  • Nerve stimulator 10 may be slaved to cardiac stimulator 20 or cardiac stimulator 20 may be slaved to nerve-stimulator 10 .
  • the output of cardiac stimulator 20 may be off whenever the output of nerve stimulator 10 is on.
  • Software controlling cardiac stimulator 20 may be designed to automatically commence cardiac pacing if the heart does not resume beating within a pre-determined interval after cessation of vagal nerve stimulation.
  • the software controlling nerve stimulator 10 may be designed to automatically stop vagal nerve stimulation if the heart has been stopped for to long. For example, a predetermined time interval may be set to automatically stop vagal stimulation. In one embodiment of the invention, if sensor 5 of the present invention indicates that not enough blood is flowing to the brain, vagal stimulation may be stopped, thereby allowing the heart to beat again.
  • sensor 5 may indicate that not enough, blood is flowing to the brain causing nerve stimulator 10 to be automatically turned off and cardiac stimulator 20 to be automatically turned on. Alternatively, the surgeon may turn on cardiac stimulator 20 to begin stimulation.
  • cardiac stimulator 20 may be intermittently stopped and, started to allows the surgeon to perform individual steps of a medical procedure.
  • Cardiac stimulator 20 may be a conventional ventricular demand pacer or dual chamber (atrial-ventricular) pacer. Cardiac stimulator 20 may be powered by AC current, DC current or it may be battery powered either by a disposable or re-chargeable battery. Cardiac stimulator 20 may be configured to synchronize activation and deactivation of breathing regulator 40 with pacing, thereby minimizing or eliminating unwanted heart and chest motion associated with the patients breathing.
  • Cardiac stimulator 20 may be any conventional pacing device suitable for ventricular demand pacing and having leads electrically coupled to a switch box. Cardiac stimulator 20 may be combined in a single unit with a switch box.
  • a switch may be incorporated in or on one of the surgeon's instruments, such as surgical site retractor, or any other location easily and quickly accessed by the surgeon for regulation of the cardiac stimulator by the surgeon.
  • the switch may be, for example, a hand switch, a foot-switch, or a voice-activated switch comprising voice-recognition technologies.
  • a single switch may be used to regulate both cardiac stimulator 20 and nerve stimulator 10 .
  • a visual and/or audible signal used to prepare a surgeon for the resumption of pacing may be incorporated into cardiac stimulator 20 .
  • a beeping tone or flashing light that increases in frequency as the pacing period ends may be used.
  • a single signaling method or device may be used for both cardiac stimulator 20 and nerve stimulator 10 .
  • Sensor 5 , nerve stimulator 10 and/or cardiac stimulator 20 may be slaved to a robotic system or a robotic system may be slaved to sensor 5 , nerve stimulator 10 and/or cardiac stimulator 20 .
  • Breathing regulator 40 and other components may also be slaved to such a system.
  • Computer and voice-controlled robotic systems that position and maneuver endoscopes and/or other surgical instruments for performing microsurgical procedures such as anastomoses through small incisions may be used by a surgeon to perform precise and delicate maneuvers. These robotic systems may allow a surgeon to perform a variety of microsurgical procedures-including endoscopic CABG. Endoscopic CABG may allow multiple occluded coronary arteries to be bypassed without a thoracotomy or mini-thoracotomy.
  • Robot systems may include head-mounted displays, which integrate 3-D visualization of surgical anatomy and related diagnostic and monitoring data, miniature high resolution 2-D and 3-D digital cameras, a computer, a high power light source and a standard video monitor.
  • System 100 may also include a breathing regulator 40 .
  • the breathing regulator 40 may be used to stimulate the phrenic nerve in order to provide a diaphragmatic pacemaker.
  • Breathing regulator 40 may comprise one or more electrodes for supplying electrical current to the phrenic nerve to control breathing during vagal and/or cardiac stimulation and/or destimulation. Electrodes used to stimulate the phrenic nerve may be, for example, non-invasive, e.g., clips, or invasive, e.g., needles or probes.
  • the application of an electrical stimulus to the phrenic nerve may include, but is not limited to bipolar and/or monopolar techniques. Different electrode positions are accessible through various access openings, for example, in the cervical or thorax regions.
  • Nerve stimulation electrodes may be positioned through a thoracotomy, sternotomy, endoscopically through a percutaneous port, through a stab wound or puncture, through a small incision, placed on the skin or in combinations thereof.
  • the present invention may include various electrodes, catheters and electrode catheters suitable for phrenic nerve stimulation to control breathing.
  • Phrenic nerve stimulation electrodes may be intravascular, patch-type, balloon-type, basket-type, umbrella-type, tape-type, cuff-type, suction-type, screwy-type, barb-type, bipolar, monopolar, metal, wire, endotracheal, endoesophageal intravascular, transcutaneous or intracutaneous electrodes.
  • Guided or steerable catheter devices comprising electrodes may be used alone- or in combination with the nerve stimulation electrodes.
  • a catheter comprising one or more wire, metal strips or metal foil electrodes or electrode arrays may be used.
  • the catheter may comprise, for example, a balloon, which may be inflated with air or liquid to press the electrodes firmly against a vessel wall that lays adjacent the phrenic nerve.
  • Phrenic nerve stimulation electrodes may be oriented in any fashion along the catheter device, including longitudinally or transversely. Various techniques such as ultrasound, fluoroscopy and echocardiography may be used to facilitate positioning of the electrodes. If desired or necessary, avoidance of obstruction of blood flow may be achieved with notched catheter designs or with catheters which incorporate one or more tunnels or passageways.
  • breathing regulator 40 may comprise a connector, which interfaces with a patients respirator, and sends a logic signal to activate or deactivate the respirator to control breathing during vagal and/or cardiac stimulation and/or destimulation.
  • FIG. 2 shows one embodiment of the present invention at 200 .
  • the elements named above may be combined or connected to a control unit along with other components.
  • Unit 200 may be used to coordinate the various elements.
  • Unit 200 may incorporate a controller as described above or any suitable processor 230 .
  • the processor may process sensed blood information from sensor 205 .
  • the controller may store and/or process such information before, during and/or after a medical procedure.
  • the patients oxygen concentration or blood pressure may be sensed, stored and processed prior to and during surgery.
  • Unit 200 may also incorporate a nerve stimulator.
  • FIG. 2 shows an electrode for nerve stimulation at 210 .
  • Electrodes used to stimulate a nerve such as the vagal nerve may be, for example, non-invasive, e.g., clips, or invasive, e.g., needles or probes.
  • the application of an electrical stimulus to the right or left vagal nerve may include, but is not limited to bipolar and/or monopolar techniques. Different electrode positions are accessible through various access openings, for example, in the cervical or thorax regions.
  • Nerve stimulation electrodes 210 may be positioned through a thoracotomy, sternotomy, endoscopically through a percutaneous port, through a stab wound or puncture, through a small incision in the neck or chest, through the internal jugular vein, the esophagus, the trachea, placed on the skin or in combinations thereof. Electrical stimulation may be carried out on the right vagal nerve, the left vagal nerve or to both nerves simultaneously or sequentially.
  • the present invention may include various electrodes, catheters and electrode catheters suitable for vagal nerve stimulation to temporarily stop or slow the beating heart alone or in combination with other heart rate inhibiting agents.
  • Nerve stimulation electrodes 210 may be endotracheal, endoesophageal, intravascular, transcutaneous, intracutaneous, patch-type, balloon-type, cuff-type; basket-type, umbrella-type, tape-type, screw-type, barb-type, metal, wire, or suction-type electrodes.
  • Guided or steerable catheter devices comprising electrodes may be used alone or in combination with the nerve stimulation electrodes 210 .
  • a catheter comprising one or more wire, metal strips or metal foil electrodes or electrode arrays maybe inserted into the internal jugular vein to make electrical contact with the wall of the internal jugular vein, and thus stimulate the vagal nerve adjacent to the internal jugular vein.
  • Access to the internal jugular vein may be via, for example, the right atrium, the right atrial appendage, the inferior vena cava or the superior vena cava.
  • the catheter may comprise, for example, a balloon, which may be inflated with air or liquid to press the electrodes firmly against the vessel wall. Similar techniques may be performed by insertion of a catheter type device into the trachea or esophagus. Additionally tracheal tubes and esophageal tubes comprising electrodes may be used.
  • Nerve stimulation electrodes 210 may be oriented in any fashion along the catheter device, including longitudinally or transversely. Various techniques such as ultrasound, fluoroscopy and echocardiography may be used to facilitate positioning of the electrodes. If desired or necessary, avoidance of obstruction of blood flow may be achieved with notched catheter designs or with catheters which incorporate one or more tunnels or passageways.
  • the location of the electrodes 210 is chosen to elicit maximum bradycardia effectiveness while minimizing current spread to adjacent tissues and vessels and to prevent the induction of post stimulation tachycardia.
  • a non-conductive material such as configurations to shield them from the surrounding tissues and vessels, while exposing their confronting edges and surfaces for positive contact with the vagal nerve or selected tissues.
  • Unit 200 may also incorporate a cardiac stimulator.
  • FIG. 2 shows a electrode for stimulation of the heart at 220 .
  • Cardiac electrodes 220 used to stimulate the heart may be, for example, non-invasive, e.g., clips, or invasive, e.g. needles or probes. Electrodes 220 may be positioned through a thoracotomy, sternotomy, endoscopically through a Terminator, a thoracotomy, sternotomy, endoscopically through a Terminator, through a stab wound or puncture, through a small incision in the chest, placed on the chest or in combinations thereof.
  • the present invention may also use various electrodes, catheters and electrode catheters and to pacing the heart, e.g., epicardial, patch-type, intravascular, balloon-type, basket-type, umbrella-type tape-type electrodes, suction-type, pacing electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes, Guided or steerable catheter devices comprising electrodes may be used alone or in combination with the electrodes. Controller 230 may be used to gather information from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220 .
  • Controller 230 may be used to gather information from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220 .
  • Controller 230 may also be used to control the stimulation levels and stimulation duration from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220 . Controller 230 may also gather and process information from sensor 205 . This information may be used to adjust-stimulation levels and stimulation times from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220 .
  • Unit 200 may incorporate one or more switches to facilitate regulation of the various components by the surgeon.
  • One example of such a switch is shown as foot pedal 250 .
  • the switch may also be, for example, a hand switch, or a voice-activated switch comprising voice-recognition technologies.
  • the switch may be incorporated in or on one of the surgeons instruments, such as surgical site retractor, or any other location easily and quickly accessed by the surgeon.
  • Unit 200 may also include a display 260 .
  • Unit 200 may also include other means of indicating the status of various components to the surgeon such as a numerical display, gauges, a monitor display or audio feedback.
  • Unit 200 may also include one or more visual and/or audible signals used to prepare a surgeon for the start or stop of nerve stimulation and/or cardiac stimulation.
  • FIG. 3 shows a flow diagram of one embodiment of the present invention.
  • the patient is prepared for a medical procedure at 500 .
  • the initial state of cerebral blood circulation is measured (Block 505 ). Such measurements may include for example blood flow, oxygen concentration, carbon dioxide concentration, etc.
  • the initial state of cerebral blood circulation is then used as a gauge to compare with the state of cerebral blood circulation during the procedure.
  • a nerve that controls the beating of the heart is stimulated.
  • a nerve may be for example a vagal nerve.
  • one or more of a variety of pharmacological agents or drugs may be delivered. These drugs may produce reversible asystole of a heart while maintaining the ability of the heart to be electrically paced.
  • a variety of pharmacological agents or drugs may also be delivered at other times during the procedure 500 . These drugs may also produce reversible asystole of a heart while maintaining the ability of the heart to be electrically paced. Other drugs may be administered for a variety of functions and purposes as described below. Drugs may be delivered at any appropriate time during the medical procedure, for example, at the beginning of the procedure, intermittently during the procedure, continuously during the procedure or following the procedure.
  • Drugs, drug formulations or compositions suitable for administration to a patient during a medical procedure may include a pharmaceutically acceptable carrier or solution in an appropriate dosage.
  • a pharmaceutically acceptable carrier or solution in an appropriate dosage.
  • pharmaceutically acceptable carriers include a number of solutions, preferably sterile, for example, water, saline. Ringers solution and/or sugar solutions such as dextrose in water or saline.
  • Carrier solutions may or may not be buffered.
  • Drug formulations or compositions may include antioxidants or preservatives such as ascorbic acid. They may also be in a pharmaceutically acceptable form for parenteral administration, for example to the cardiovascular system, or directly to the heart, such as intracoronary infusion or injection. Drug formulations or compositions may comprise agents that provide a synergistic effect when administered together. A synergistic effect between two or more drugs or agents may reduce the amount that normally is required for therapeutic delivery of an individual drug or agent. Two or more drugs may be administered, for example, sequentially or simultaneously. Drugs may be administered via one or more bolus injections and/or infusions or combinations thereof. The injections and/or infusions may be continuous or intermittent.
  • Drugs may be administered, for example, systemically or locally, for example, to the heart, to a coronary artery and/or vein, to a pulmonary artery and/or vein, to the right atrium and/or ventricle, to the left atrium and/or ventricle to the aorta, to the AV node, to the SA node, to a nerve and/or to the coronary sinus.
  • Drugs may be administered or delivered via intravenous, intracoronary and/or intraventricular administration in a suitable carrier.
  • Examples of arteries that may be used to deliver drugs to the AV node include the AV node artery, the right coronary artery, the right descending coronary artery, the left coronary artery, the let anterior descending coronary artery and Kugel's artery.
  • Drugs may be delivered systemically, for example, via oral, transdermal, intranasal suppository or inhalation methods. Drugs also may be delivered via a pill, a spray, a cream, an ointment or a medicament formulation.
  • Drugs may be delivered via a drug delivery device that may comprise a catheter, such as a drug delivery catheter or a guide catheter, a patch, such as a transepicardial patch that slowly releases drugs directly into the myocardium, a cannula, a pump and/or a hypodermic needle and syringe assembly.
  • a drug delivery catheter may include an expandable member, e.g., a low-pressure balloon, and a shaft having a distal portion, wherein the expandable member is disposed along the distal portion.
  • a catheter for drug delivery may comprise one or more lumens and may be delivered endovascularly via insertion into a blood vessel, e.g., an artery such as a femoral, radial, subclavian or coronary artery.
  • the catheter can be guided into a desired position using various guidance techniques, e.g., flouroscopic guidance and/or a guiding catheter or guide wire techniques.
  • Drugs may be delivered via an iontophoretic drug delivery device placed on the heart.
  • the delivery of ionized drugs may be enhanced via a small current applied across two electrodes. Positive ions may be introduced into the tissues from the positive pole, or negative ions from the negative pole.
  • the use of iontophoresis may markedly facilitate the transport of certain ionized drug molecules.
  • lidocaine hydrochloride may be applied to the heart via a drug patch comprising the drug.
  • a positive electrode could be placed over the patch and current passed.
  • the negative electrode would contact the heart or other body part at some desired distance point to complete the circuit.
  • One or more of the electrodes may also be used as nerve stimulation electrodes 210 or as cardiac stimulation electrodes 220 .
  • the two divisions of the autonomic nervous system that regulate the heart have opposite functions.
  • the adrenergic or sympathetic nervous system increases heart rate by releasing epinephrine and norepinephrine.
  • the parasympathetic system also known as the cholinergic nervous system or the vagal nervous system decreases heart rate by releasing acetylcholine.
  • Catecholamines such as norepinephrine (also called noradrenaline) and epinephrine (also called adrenaline) are agonists for beta-adrenergic receptors.
  • An agonist is a stimulant biomolecule or agent that binds to a receptor.
  • Beta-adrenergic receptor blocking agents compete with beta-adrenergic receptor stimulating agents for available beta-receptor sites.
  • receptor blocking agents also known as beta-adrenergic blockade
  • the chronotropic or heart rate, inotropic or contractility, and vasodilator responses to receptor stimulating agents are decreased proportionately. Therefore, beta-adrenergic receptor blocking agents are agents that are capable of blocking beta-adrenergic receptor sites.
  • beta-adrenergic receptors are concerned with contractility and heart rate
  • stimulation of beta-adrenergic receptors increases heart rate, the contractility of the heart and the rate of conductor of electrical impulses through the AV node and the conduction system.
  • Drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized (synthetic analogues) beta-adrenergic receptor blocking agents.
  • Beta-adrenergic receptor or ⁇ -adrenegic blocking agents are also known as beta-blockers or ⁇ -blockers and as class II antiarrhythmics.
  • beta-blocker may refer to one or more agents that antagonize the effects of beta-stimulating catecholamines by blocking the catecholamines ines from binding to the beta-receptors.
  • beta-blockers include, but are not limited to a acebutolol, alprenolol, atenolol, betantolol, betaxolol, becantolol, bisoprolol, carterolol, celiprblol, chlorthalidone, esmolol, labetalol, metoprolol, nadolol, penbutolol, pindolol, propranolol, oxprenolol, sotalol, teratolo, timolol and combinations, mixtures and salts thereof.
  • beta-blockers may be reversed by administration of beta-receptor agonists, e.g., dobutamine or isoproterenol.
  • beta-receptor agonists e.g., dobutamine or isoproterenol.
  • the parasympathetic or cholinergic system participates in control of heart rate via the sinoatrial (SA) node, where it reduces heart rate.
  • Other cholinergic effects include inhibition of the AV node and an inhibitory effect on contractile force.
  • the cholinergic system acts through the vagal nerve to release acetylcholine, which, in turn, stimulates cholinergic receptors.
  • Cholinergic receptors are also known as muscarinic receptors. Stimulation of the cholinergic receptors decreases the formation of CAMP. Stimulation of cholinergic receptors generally has an opposite effect on heart rate compared to stimulation of beta-adrenergic receptors.
  • beta-adrenergic stimulation increases heart rate, whereas cholinergic stimulation decreases it.
  • vagal tone is high and adrenergic tone is low, there is a marked slowing, of the heart (sinus bradycardia).
  • Acetylcholine effectively reduces the amplitude, rate of increase and duration of the SA node action potential.
  • the SA node does not arrest. Rather, pacemaker function may shift to cells that fire at a slower rate.
  • acetylcholine may help open certain potassium channels thereby creating an outward flow of potassium ions and hyperpolarization. Acetylcholine also slows conduction through the AV node.
  • Drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized (synthetic analogues) cholinergic agent.
  • the term “cholinergic agent” appearing herein may refer to one or more cholinergic receptor modulators, or agonists.
  • Examples of cholinergic agents include, but are not limited to, acetylcholine, carbachol (carbamyl choline chloride), bethanechol, methacholine, arecoline, norarecoline and combinations, mixtures and/or salts thereof.
  • Drugs, drug formulations and/or drug compositons that may be used according to this invention may include any naturally occurring or chemically synthesized cholinesterase inhibitor.
  • the term “cholinesterase inhibitor” appearing herein may refer to one or more agents that prolong the action of acetylcholine by inhibiting its destruction or hydrolysis by cholinesterase. Cholinesterase inhibitors are also known as acetylcholinesterase inhibitors. Examples of cholinesterase inhibitors include, but are not limited to, edrophonium, neostigmine, neostigmine methylsulfate; pyridostigmine, tacrine and combinations, mixtures and/or salts thereof.
  • ion-selective channels within certain cell membranes. These ion selective channels include calcium channels, sodium channels and/or potassium channels. Therefore, other drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized calcium channel blocker.
  • Calcium channel blockers inhibit the inward flux of calcium ions across cell membranes of arterial smooth muscle cells and myocardial cells. Therefore, the term “calcium channel blocker” appearing herein may refer to one or more agents that inhibit or block the flow of calcium ions across a cell membrane.
  • the calcium channel is generally concerned with the triggering of the contractile cycle. Calcium channel, blockers are also known as calcium ion influx inhibitors, slow channel blockers, calcium ion antagonists, calcium channel antagonist drugs and as class IV antiarrhythmics.
  • a commonly used calcium channel blocker is verapamil.
  • a calcium channel blocker e.g., verapamil
  • a calcium channel blocker generally prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner, since the electrical activity through the AV node depends significantly upon the influx of calcium ions through the slow channel.
  • a calcium channel blocker has the ability to slow a patients heart rate, as well as produce AV block.
  • calcium channel blockers examples include, but are not limited to, amiloride, amlodipine, bepridil, diltiazem, felodipine, isradipine, mibefradil, nicardipine, nifedipine (dihydropyridines), nickel, nimodinpine, nisoldipine, nitric oxide (NO), norverapamil and veraparhil and combinations, mixtures and/or salts thereof.
  • Verapamil and diltiazem are very effective at inhibiting the AV node, whereas drugs of the nifedipine family have a lesser inhibitory effect on the AV node.
  • Nitric oxide (NO) indirectly promotes calcium channel closure.
  • NO may be used to inhibit contraction. NO may also be used to inhibit sympathetic outflow, lessen the release of norepinephrine, cause vasodilation, decrease heart rate and decrease contractility. In the SA node, cholinergic stimulation leads to formation of NO.
  • drugs, drug formulations and/or drug compositions may include any naturally occurring or chemically synthesized sodium channel blocker.
  • Sodium channel blockers are also known as sodium channel inhibitors, sodium channel blocking agents, rapid channel blockers or rapid channel inhibitors.
  • Antiarrhythmic agents that inhibit or block the sodium channel are known as class I antiarrhythmics, examples include, but are not limited to, quinidine and quinidine-like agents, lidocaine and lidocaine-like agents, tetrodotoxin, encainide, flecainid and combinatons, mixtures and/or salts thereof.
  • sodium channel blocker may refer to one or more agents that inhibit or block the flow of sodium ions across a cell membrane or remove the potential difference across a cell membrane.
  • the sodium channel may also be totally inhibited by increasing the extracellular potassium levels to depolarizing hyperkalemic values, which remove the potential difference across the cell membrane. The result is inhibition of cardiac contraction with cardiac arrest (cardioplegia). The opening of the sodium-channel (influx of sodium) is for swift conduction of the electrical impulse throughout the heart.
  • potassium channel agent may refer to one or more agents that impact the flow of potassium ions across the cell membrane.
  • the first type of channel is voltage-gated and the second type is ligand-gated.
  • Acetylcholine-activated potassium channels which are ligand-gated channels, open in response to vagal stimulation and the release of acetylcholine. Opening of the potassium channel causes hyperpolarization, which decreases the rate at which the activation threshold is reached.
  • Adenosine is one example of a potassium channel opener.
  • Adenosine slows conduction through the AV node.
  • Adenosine a breakdown product of adenosine triphosphate inhibits the AV node and atria.
  • adenosine causes the shortening of the action potential duration and causes hyperpolarization.
  • adenosine has similar effects and also decreases the action potential amplitude and the rate of increase of the action potential.
  • Adenosine is also a direct vasodilator by its actions on the adenosine receptor on vascular smooth muscle cells.
  • adenosine acts as a negative neuromodulator, thereby inhibiting release of norepinephrine.
  • Class III antiarrhythmic agents also known as potassium channel inhibitors lengthen the action potential duration and refractoriness by blocking the outward potassium channel to prolong the action potential.
  • Amiodarone and d-sotalol are both examples of class III antiarrhythmic agents.
  • Potassium is the most common component in cardioplegic solutions. High extracellular potassium levels reduce the membrane resting potential. Opening of the sodium channel, which normally allows rapid sodium influx during the upstroke of the action potential, is therefore inactivated because of a reduction in the membrane resting potential.
  • the present invention may be combined with conventional CPB, the induced asystole as described by this invention may serve as a substitute for conventional cardioplegic arrest.
  • the combination of drugs and vagal stimulation may be used as a cardioplegic agent in a variety of medical procedures.
  • Drugs, drug formulations and/or drug compositions that may be used during according to this invention may comprise one or more of any naturally occurring or chemically synthesized beta-blocker, cholinergic agent, cholinesterase inhibitor, calcium channel blocker, sodium channel blocker, potassium channel agent, adenosine, adenosine receptor agonist, adenosine deaminase inhibitor, dipyridamole, monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, bradykinin agents, serotoninergic agonist, antiarrythmic agents, cardiac glycosides, local anesthetics and combinations or mixtures thereof. Digitalis and digoxin both inhibit the sodium pump.
  • Digitalis is a natural inotrope derived from plant material, while digoxin is a synthesized inotrope. Dipyridamole inhibits adenosine deaminase, which breaks down adenosine. Drugs, drug formulations and/or drug compositions capable of reversibly suppressing autonomous electrical conduction at the SA and/or AV node, while still allowing the heart to be electrically paced to maintain cardiac output may be used according to this invention.
  • thee cardiac asystole produced in accordance with the resent invention is reversible e.g., chemically such as by the administration of atropine or by natural forces.
  • Beta-adrenergic stimulation or administration of calcium solutions may be used to reverse the effects of a calcium channel blocker such as verapamil.
  • Agents that promote heart rate and/or contraction may be used in a preferred embodiment of the present invention.
  • dopamine a natural catbcliplamine
  • Positive inotropes are agents that specifically increase the force of contraction of the heart.
  • Glucagon a naturally occurring hormone, is known to increase heart rate and contractility.
  • Glucagon may be used to reverse the effects of a beta-blocker since its effects bypass the beta receptor.
  • Forskolin is known to increase heart rate and contractility.
  • epinephrine and norepiriephrine naturally increase heart rate and contractility.
  • Thyroid hormone, phosphodiesterase inhibitors and prostacyclin, a prostaglandin are also known, to increase heart rate and contractility.
  • methylxanthines are known to prevent adenosine from interacting with its cell receptors.
  • vagal nerve stimulation prevents the heart from contracting. This non-contraction must then be followed by periods. Without vagal nerve stimulation during which the heart is allowed to contract, and blood flow is restored throughout the body.
  • the state of cerebral blood circulation may be monitored. This monitoring may occur at specific points during the procedure, for example, as shown at block 517 . Alternatively, monitoring may occur continuously. If cerebral blood circulation is sufficient, then all or a portion of the medical procedure may be carried out (Block 520 ). However, if the state of cerebral blood circulation is not sufficient, then a signal may indicate that the state of blood circulation to the brain is insufficient.
  • the surgeon may proceed to block 530 , where the nerve stimulation is ceased an the heart is allowed to contract.
  • the cardiac stimulator may be used to cause the heart to contract.
  • unit 200 may automatically proceed to Block 530 to cease nerve stimulation.
  • Unit 200 may automatically begin cardiac stimulation.
  • the state of cerebral blood circulation sensed by sensor 5 may be communicated to the surgeon by a number of suitable means.
  • the ambient blood flow may be indicated on a display or monitor.
  • a visual or audio signal may indicate when the level of cerebral blood flow reaches a certain level, e.g. when blood flow is insufficient.
  • the system of the present invention may “lock” the controls of the vagal stimulator in an “off” state when cerebral blood flow reaches a predetermined condition, thereby indicating that blood flow is insufficient. The system may then release the controls when the state of cerebral blood circulation sensed by the sensor is again sufficient.
  • the amount of vagal nerve stimulation used may be adjusted based on the output of the sensor 5 .
  • the level of stimulation may be lowered or the duration of stimulation may be lowered if the sensor indicates that cerebral blood circulation at 517 is insufficient. This adjustment may be automatic or may be controlled by the surgeon.
  • a medical procedure may be performed or begun. Such a procedure may be for example surgery on the heart. Alternatively, the procedure may be surgery performed on another organ of the body.
  • medical procedure may mean any one or more medical or surgical procedures such as, for example cardiac surgery, performed with or without cardiopulmonary bypass (CPB) circuits, heart valve repair, heart valve replacement, MAZE procedures, transmyocardial revascularization (TMR), CABG procedures, anastomosis procedures, non-surgical procedures, fluoroscpic procedures, beating heart surgery, vascular surgery, neurosurgery, brain surgery, electrophysiology procedures diagnostic and therapeutic procedures, ablation procedures, ablation of arrhythmias, endovascular procedures, treatment of the liver, spleen, heart, lungs, and major blood vessels, aneurysm repair, imaging procedures of the heart and great vessels, CAT scans or MRI procedures, pharmacological therapies, drug delivery procedures, gene therapies, cellular therapies, cancer therapies, radiation therapies, genetic, cellular, tissue and/or organ manipulation or transplantation procedures, coronary angioplasty procedures, placement or delivery of coated or noncoated stents, atherectomy procedures, atherosclerotic plaque manipulation and/or removal procedures
  • CPB
  • the medical procedure comprises one or more medical devices, e.g., coated stents
  • these devices may be coated with one or more radioactive materials and/or biological agents such as, for example, an anticoagulant agent, an antithrombotic agent, a clotting agent, a platelet agent, an anti-inflammatory agent an antibody, an antigen, an immunoglobulin, a defense agent, an enzyme, a hormone, a growth factor, a neurotransmitter, a cytokine, a blood agent, a regulatory agent, a transport agent, a fibrous agent, a protein, a peptide, a proteoglycan, a toxin, an antibiotic agent, an antibacterial agent, an antimicrobial agent, a bacterial agent or component, hyaluronic acid a polysaccharide, a carbohydrate, a fatty acid, a catalyst, a drug, a vitamin, a DNA segment, a RNA segment, a nucleic acid, a lectin, an anti
  • the medical procedure may be non-invasive, minimally invasive and/or invasive.
  • the medical procedure- may entail a port-access approach, a partially or totally endoscopic approach, a sternotomy approach or a thoracotomy approach.
  • the medical procedure may include the use of various mechanical stabilization devices or techniques as well as various robotic or imaging systems.
  • the heart may be temporarily slowed or intermittently stopped for short periods of time to permit the surgeon to accomplish the required surgical task and yet still allow the heart itself to supply blood circulation to the body.
  • stimulation of the vagus nerve in order to temporarily and intermittently slow or stop the heart is described in U.S. Pat. No. 6,006,134 entitled “Method and Device for Electronically Controlling the Beating of a Heart Using Venous Electrical Stimulation of Nerve Fibers”, Dec. 21, 1999, to Hill and Junkman. This patent is assigned to Medtronic, Inc. and is incorporated herein by reference.
  • the state of cerebral blood circulation may be monitored constantly or intermittently as described above. An assessment, for example, of the amount of blood flowing to the brain may again be taken at block 525 . If the state of cerebral blood circulation is sufficient the physician may continue with the medical procedure that is in progress. However, if the state of cerebral blood circulation is not sufficient, then the sensor 5 may indicate that blood circulation to the brain is insufficient. If the sensor indicates that blood circulation is insufficient, the surgeon may proceed to Block 530 , where the nerve stimulation is ceased. The heart will therefore be allowed to contract and thus blood will again be allowed to flow to the brain and vital organs. The cardiac stimulator maybe used to cause the heart to contract. Alternatively, unit 200 may automatically proceed to Block 530 to cease nerve stimulation.
  • Unit 200 may automatically begin cardiac stimulation. Additionally the amount of vagal nerve stimulation used may be adjusted based on the output of the sensor 5 . For example, the level of stimulation may be lowered or the duration of stimulation may be lowered if the sensor indicates that cerebral blood circulation at 525 is insufficient.
  • the medical procedure or one phase of the procedure is completed at 520 .
  • cardiac contractions are allowed to occur (Block 530 ). Cardiac contractions may need to occur intermittently during the procedure to ensure adequate blood flow.
  • the stimulation from the nerve stimulator 10 is stopped or slowed enough to allow the heart to contract. For example, the vagal nerve stimulation is removed, thereby allowing cardiac contractions to occur.
  • the heart may be stimulated to ensure that cardiac contractions occur (Block 535 ).
  • cardiac stimulator 20 may be used to apply pacing pulses to the heart to encourage the heart to contract normally.
  • the pacing pulses may be applied to the ventricle as is well known in the field.
  • the amount of cardiac stimulation used may be adjusted based on the output of the sensor 5 . For example, the level of stimulation may, be increased or the duration of stimulation may be increased if the sensor indicates that cerebral blood circulation at 525 is insufficient.
  • the present invention permits the heart to be stilled or quiescent for selected and controllable periods of time in order to permit a medical procedure to be performed. While such a period of stillness or quiescence is desired, it must not last too long, otherwise insufficient blood and oxygen is delivered to organs. Thus, it is necessary to have the periods when the heart is beating (Blocks 530 , 535 ).
  • the state of cerebral blood circulation for example, sensed by sensor 5 while the heart is beating may be communicated to the surgeon by a number of suitable means.
  • ambient blood flow may be indicated on a display or monitor.
  • a visual or audio signal may indicate when the level of cerebral blood flow reaches a certain level, e.g. when blood flow is insufficient.
  • the system of the present invention may “lock” the controls of the cardiac stimulator in an “on” state when the state of cerebral blood circulation reaches a predetermined condition, thereby indicating that blood circulation is insufficient. The system may then release the controls when the state of blood circulation sensed by the sensor is again sufficient.
  • the heart may again be stilled using the methods of stilling the heart described above. Therefore from Block 530 or Block 535 , the method may be repeated (as in the loop designated by 540 ). For example, the heart may again be prevented from contracting by stimulation of the vagal nerve ( 510 ). Additional drugs may be delivered or the drugs previously administered may continue to be administered.
  • This cycle may be repeated until the procedure, such as the surgery, is completed.
  • sensor 5 enables monitoring of the state of blood circulation and, if necessary, appropriate adjustment of nerve stimulation and cardiac stimulation to ensure sufficient blood circulation.
  • the surgical procedure at 520 may require several stitches to be made by the surgeon.
  • the surgeon may stimulate the vagal nerve, at 510 to stop the heart. Then the surgeon may make the first stitch at 520 .
  • the surgeon may then reduce or halt stimulation at 530 and allow the heart to contract.
  • the surgeon may also pace the heart at 535 .
  • the surgeon may return to 510 to inhibit contractions of the heart.
  • the surgeon will then make the second stitch. This process may be repeated (the loop designated by 540 may be repeated) until all the required stitches have been made.
  • the state of blood circulation is monitored continuously or, for example at Blocks 517 and 525 by sensor 5 . The procedure may proceed uninterrupted if the state of blood circulation remains sufficient.
  • step 535 may be performed until the heart is beating normally.
  • Step 545 may be continued until, the physician is satisfied that the heart is beating normally and the state of blood circulation has reached an acceptable level.
  • FIG. 4 is a timeline showing the relationship of a sensor, a nerve stimulator and a cardiac stimulator in one embodiment of the present invention.
  • Point 610 indicates a point before the medical procedure has begun. At this point 610 , both nerve stimulation and cardiac stimulation are off. At point 610 , the heart is beating regularly. The patients state of cerebral blood circulation, for example, may be measured by sensor 5 at point 610 . Thus sensor 5 may be turned on at point 610 .
  • nerve stimulation is turned on to inhibit beating of the heart.
  • the vagal nerve stimulation is on and the cardiac stimulation is off. This is the condition of the two types of stimulation at step 520 described above.
  • sensor 5 is on throughout the entire procedure.
  • sensor 5 may be turned on during phase 601 to check the state of cerebral blood circulation (as described at Block 517 ).
  • Point 611 is a representative point during phase 601 .
  • the contractions of the heart are stilled or substantially slowed.
  • the current state of cerebral blood-circulation may be determined (as described at Blocks 517 and 525 ). If the state of cerebral blood circulation at point 611 is sufficient, then the medical procedure can proceed (as described at Block 520 ). However, if the state of cerebral blood circulation is not sufficient at point 611 , sensor 5 may provide a signal indicating that the state of cerebral blood circulation is insufficient. The surgeon may then proceed immediately to phase 602 . Alternatively, control unit 200 may automatically proceed to phase 602 after providing the signal.
  • the amount of vagal stimulation used may be adjusted based on the output of the sensor 5 .
  • the level of stimulation may be decreased or the duration of stimulation may be decreased if the sensor indicates that the state of blood circulation, at point 611 is insufficient.
  • the vagal stimulation is turned off (as described at step 530 ) and the cardiac stimulation may be turned on (as described at 535 ).
  • Point 612 is a representative point during phase 602 . At point 612 , the contractions are allowed and/or may be induced. In one embodiment, sensor 5 is still on during phase 602 . Alternatively, sensor 5 may be turned on during phase 602 to check the state of blood circulation to the brain.
  • the amount of cardiac stimulation used may be adjusted based on the output of the sensor 5 .
  • the level of stimulation may be increased or the duration of stimulation may be increased if the sensor indicates that cerebral blood circulation at point 612 is insufficient.
  • the vagal nerve stimulation is again turned on and the cardiac stimulation is turned off.
  • sensor 5 may still be on.
  • the amount or duration of vagal stimulation during phase 603 may be different than the amount or duration of vagal stimulation during phase 601 , based on the data gathered from sensor 5 during phase 601 .
  • the current state of cerebral blood circulation may again be determined during phase 603 (as described at Block 525 ).
  • Point 613 is a representative point during phase 603 . If the state of blood circulation at point 613 is sufficient, then the medical procedure can proceed (as described in step 520 ). However, if the state of blood circulation is not sufficient at point 611 , sensor 5 may provide a signal indicating that blood circulation is insufficient. The surgeon may then proceed immediately to phase 602 . Alternatively control unit 200 may automatically proceed to phase 602 after providing the signal. Additionally, the amount of vagal stimulation used may again be adjusted based on the output of the sensor 5 .
  • phase 604 the vagal stimulation is again turned off and the cardiac stimulation may again be turned on.
  • the amount or duration of cardiac stimulation during phase 604 may be different than the amount or duration of cardiac stimulation during phase 602 , based on the data gathered from sensor 5 during the previous phases.
  • the method of the present invention may be repeated as necessary until a point is reached, represented by point 615 , when the necessary medical procedures are completed.
  • nerve stimulation is off although cardiac stimulation may be left on in order to pace the heart to its normal rhythm.
  • the state of cerebral blood circulation may be checked for a final time (as described at 545 ).

Abstract

A method of performing a medical procedure, such as surgery, is provided. The system comprises a sensor to sense a biological characteristic, such as a chemical, physical or physiological characteristic of a bodily tissue or fluid. The method also comprises a nerve stimulator in communication with the sensor to inhibit beating of a heart when the sensor senses the biological characteristic at a first value; and a cardiac stimulator in communication with the sensor to stimulate beating of the heart when the sensor senses the biological characteristic at a second value.

Description

    PRIORITY
  • Applicants claim priority to co-pending U.S. patent application Ser. No. 09/669,961 filed Sep. 26, 2000.
  • FIELD OF THE INVENTION
  • This invention relates to methods and systems for performing a medical procedure, especially procedures during which it is necessary to adjust the beating of the heart in order to allow the medical procedure to be performed on the heart or another organ. More particularly, this invention relates to methods and systems for monitoring and controlling one or more physiological and/or chemical parameters of a fluid such as blood or oxygen in the systemic and/or pulmonary circulatory systems during such a medical procedure.
  • BACKGROUND OF THE INVENTION
  • The current leading cause of death in the United States is coronary artery disease in which the coronary arteries are blocked by atherosclerotic plaques or deposits of fat. The typical treatment to relieve a partially or fully blocked coronary artery is coronary artery bypass graph (CABG) surgery.
  • CABG surgery, also known as “heart bypass” surgery, generally entails using a graph to bypass the coronary obstruction. The procedure is generally lengthy, traumatic and subject to patient risks. Among the risk factors involved is the use of a cardiopulmonary bypass (CPB) circuit, also known as a “heart-lung machine”, to pump blood and oxygenate the blood so that the patients heart may be stopped during the surgery.
  • Conventional CABG procedures are typically conducted on a stopped heart while the patient is on a (CPB) circuit. A stopped heart and a CPB circuit enables a surgeon to work in a bloodless, still operative field. However, there a number of problems associated with CABG procedures performed while on CPB including the initiation of a systemic inflammatory response due to interactions of blood elements with the artificial material surfaces of the CPB circuit and global myocardial ischemia due to cardioplegic cardiac arrest. For these reasons, avoiding the use of CPB or cardioplegic cardiac arrest may help minimize post-operative complications.
  • One method, as disclosed in U.S. Pat. No. 5,651,378 to Matheny and Taylor and in U.S. Pat. No. 5,913,876 to Taylor et al., for facilitating coronary bypass surgery on a beating heart and thereby avoid the use of CPB and cardioplegic cardiac arrest includes stimulating the vagal nerve electrically in order to temporarily stop or substantially reduce the beating of the heart. This may be followed by pacing the heart to start its beating.
  • Another method, as disclosed in two published PCT applications, WO 99/09971 and WO 99/09973, both to Puskas, involves stopping the beating of the heart during coronary bypass surgery using electrical stimulation of the vagal nerve in combination with administration of drugs. Another method, as disclosed in U.S. Pat. No. 6,060,454 to Duhaylongsod, involves stopping the beating of the heart during coronary bypass surgery via the local delivery of drugs to the heart.
  • Although it is desirable to stop the heart for a period of time in order to allow the surgeon to accomplish a required task without interference from heart movement, i.e. a motionless operative field, it is undesirable to have the heart stopped for too long a period of time since the body needs, among other things, constant supply of oxygen. In fact it is particularly important to maintain sufficient blood flow, and therefore oxygen flow, to the brain. A system for sensing biological parameters, such as the amount of blood flow or oxygen flow to the brain, could help determine whether these parameters are sufficient during a medical procedure.
  • It would be desirable to provide a method for controllably stopping or slowing the heart intermittently in order to control blood flow in the systemic and/or pulmonary circulatory systems during a medical procedure.
  • Additionally, it would be desirable to provide a means for monitoring one or more chemical, physical or physiological characteristics of a bodily tissue or fluid during the procedure.
  • Additionally, it would be desirable to provide a method for controllably stopping or slowing the heart intermittently for diagnostic or therapeutic purposes.
  • Additionally, it would, be desirable to provide a method for controllably stopping or slowing the heart intermittently in order to perform surgery on the heart or another organ.
  • SUMMARY OF THE INVENTION
  • One aspect of the present invention provides a system for performing a medical procedure. The system includes a sensor to sense a biological characteristic, a nerve stimulator to inhibit beating of a heart when the sensor senses the biological characteristic at a first value and a cardiac stimulator to stimulate beating of the heart when the sensor senses the biological characteristic at a second value.
  • The biological characteristic maybe a chemical characteristic of a tissue, a chemical characteristic of a fluid, a physical characteristic of a tissue, a physical characteristic of a fluid, a physiological characteristic of a tissue, and a physiological characteristic of a fluid. The biological characteristic may be a characteristic of a body component such as the blood, blood, cardiac tissue, or a nerve. The biological characteristic may be fluid flow, fluid pressure, mechanical pressure, temperature, electrical current, chemical concentration, presence of a protein, concentration of a protein, presence of a peptide, concentration of a peptide, a metabolic process, presence of a gas, concentration of a gas, presence of oxygen, concentration of oxygen, presence of carbon dioxide, concentration of carbon dioxide.
  • The system may also include drug delivery means such as a spray, a cream, an ointment, a medicament, a pill, a patch, a catheter, a cannula, a needle and syringe, a pump, and an iontophoretic drug delivery device to deliver at least one drug during the procedure. The drug may be a beta-blocker, a cholinergic agent, a cholinesterase inhibitor, a calcium channel blocker, a sodium, channel blocker, a potassium channel agent, adenosine, an adenosine, receptor agonist, an adenosine deaminase inhibitor, dipyridamole, a monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, a bradykinin agent, a serotoninergic agonist, an antiarrythmic agent, a cardiac glycoside, a local anesthetic, atropine, a calcium solution, an agent that promotes heart rate, an agent that promotes heart contractions, dopamine, a catecholamine, an inotrope glucagon, a hormoone, forskolin, epinephrine, norepinephrine, thyroid hormone, a phosphodiesterase inhibitor prostacyclin, prostagiandin and a methylxanthine. The drug may be naturally occurring or chemically syrithesized.
  • The nerve stimulator may stimulate a nerve such as a vagal nerve, a carotid sinus nerve, a fat pad. The nerve stimulation may be stopped automatically when the sensor senses the biblogical characteristic at the second value. Cardiac stimulation may begin automatically when the sensor senses the biological characteristic at the second value. The nerve stimulator may be, for example, one or more electrodes, such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • The sensor may be an imaging system, an electrical sensor, a chemical sensor, an electromagnetic interference sensor, an electrochemical sensor, a pressure sensor, a sound wave sensor, a magnetic sensor, an ultraviolet sensor, a visible light sensor, an infrared sensor, a radiation sensor, a flow sensor, a temperature sensor, a gas sensor, an optical sensor, a pH sensor, a potentiometric sensor, a fluorescence sensor and a biosensor.
  • The cardiac stimulator may be, for example, one or more electrodes, such as cardiac stimulation electrodes, clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrode intravascular electrodes, balloon-type electrodes basket-type electrodes, tape-type electrodes, umbrella type electrodes, suction-type electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes.
  • The system may also include a breathing regulator, which may control a respirator. The breathing regulator may stimulate a phrenic nerve. The breathing regulator may be, for example, one or more electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire-electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • The medical procedure may be a surgical procedure, a non-surgical procedures, a fluoroscopic procedure, a cardiac procedure, a vascular procedure, a neurosurgical procedure, an electrophysiological procedure, a diagnostic procedure, a therapeutic procedure, an ablation procedure, an endovascular procedure, a liver procedure, a spleen procedure, a pulmonary procedure, an aneurysm repair, an imaging procedure, a CAT scan procedure, a MRI procedure, a pharmacological therapy, a drug delivery procedure, a biological delivery procedure, a genetic therapy, a cellular therapy, a cancer therapy, a radiation therapy, a transplantation procedure, a coronary angioplasty procedure, a stent delivery procedure, an atherectomy procedure, a procedure that requires precise control of cardiac motion, a procedure that requires precise control of bleeding, a non-invasive procedure, a minimally invasive procedure, an invasive procedure, a port-access procedure, an endoscopic procedure, a sternotomy procedure, a thoracotomy procedure and a robotic procedure.
  • Another aspect of the present invention provides a method for performing a medical procedure. A biological characteristic is sensed at a first value and a first signal related to the sensed biological characteristic is sent. Beating of a heart is inhibited in response to the first signal. The medical procedure is then performed. The biological characteristic is then sensed at a second value and a second signal related to the sensed biological characteristic at the second value is sent. Beating of the heart is stimulated in response to the second signal.
  • Beating of the heart may be inhibited automatically in response to the first signal. Beating of the heart may be stimulated automatically in response to the second signal. At last one drug may be delivered during the medical procedure. A nerve may be stimulated to inhibit beating of the heart. Breathing may be stopped while beating of the heart is inhibited. Breathing may be stopped automatically.
  • The biological characteristic may be a characteristic of blood, a characteristic of cardiac tissue, a characteristic of a nerve, a fluid flow characteristic, a pressure characteristic, a temperature characteristic, an electrical characteristic, a chemical concentration, a presence of a protein, a concentration of a protein, a presence of a peptide, a component of a metabolic process, a presence of a gas, a concentration of a gas, a presence of oxygen, a concentration of oxygen, a presence of carbon dioxide, a concentration of carbon dioxide, a chemical characteristic, a physical characteristic, and a physiological characteristic.
  • Another aspect of the present invention provides a device for performing a medical procedure. The device includes a processor, a sensor to sense a biological characteristic and at least one nerve stimulation electrode. The processor receives a signal from the sensor and adjusts output from the nerve stimulation electrode in response to the signal.
  • The sensor may be an imaging system, an electrical sensor, a chemical sensor, an electromagnetic interference sensor, an electrochemical sensor, a pressure sensor, a sound wave sensor, a magnetic sensor, an ultraviolet sensor, a visible light sensor, an infrared sensor, a radiation sensor, a flow sensor, a temperature sensor, a gas sensor, an optical sensor, a pH sensor, a potentiometric sensor, a fluorescence sensor and a biosensor.
  • The nerve stimulation electrode may be one or more electrodes, such as endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
  • The device may also include a cardiac stimulation electrode to stimulate beating of the heart. The processor receives a signal from the sensor and adjusts output from the cardiac stimulation electrode in response to the signal. The cardiac electrode may be, for example, one or more electrodes such as clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrodes, intravascular electrodes, balloon-type electrodes, basket-type electrodes, tape-type electrodes, umbrella-type electrodes, suction-type electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes.
  • The device may also include a breathing regulation electrode for controlling breathing. The processor adjusts the output from the breathing regulation electrode in response to the signal. The breathing regulation electrode may be, for example, one or more electrodes such as nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes; basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes; clip electrodes, needle electrodes and probe electrodes.
  • The device may also include a drug pump for delivering at least one drug. The processor adjusts the output of the drug. The drug may be, for example, a beta-blocker, a cholinergic agent, a cholinesterase inhibitor, a calcium channel blocker, a sodium channel-blocker, a potassium channel agent, adenosine, an adenosine receptor agonist, an adenosine deamrinase inhibitor, dipyridamole, a monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, a bradykinin agent, a serotoninergic agonist, an antiarrythmic agent, a cardiac glycoside, a local anesthetic, atropine, a calcium solution, an agent that promotes heart rate, an, agent that promotes heart contractions, dopamine, catecholamine, an inotrope glucagon, a hormone, forskolin, epinephrine norepinephrine, thyroid hormone, a phosphodiesterase inhibitor, prostacyclin, prostaglandin and a methylxanthine.
  • The foregoing, and other, features and advantages of the invention will become further apparent from the following detailed description of the presently preferred embodiments, read in conjunction with the accompanying drawings. The detailed description and drawings are merely illustrative of the invention rather than limiting, the scope of the invention being defined by the appended claims in equivalence thereof.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a schematic view of one embodiment of a system for monitoring at least one chemical, physical or physiological characteristic during a medical procedure in accordance with the present invention;
  • FIG. 2 is a schematic view of one embodiment of a medical device in accordance with the present invention;
  • FIG. 3 is a flow diagram of one embodiment of a method of performing a medical procedure in accordance with the present invention; and
  • FIG. 4 is a timeline view of one embodiment of a system for monitoring at least one chemical, physical or physiological characteristic during a medical procedure in accordance with the present invention.
  • DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
  • FIG. 1 shows a schematic view of one embodiment of a system for performing a medical procedure in accordance with the present invention at 100. System 100 comprises a sensor 5, a nerve stimulator 10, and a cardiac stimulator 20. System 100 may also feature a controller 30 and a breathing regulator 40.
  • Sensor 5 may be any suitable blood gas sensor for measuring the concentration or saturation of a gas in the blood stream. For example, sensor 5 may be a sensor for measuring the concentration or saturation of oxygen or carbon dioxide in the blood. Alternatively, sensor 5 may be any suitable sensor for measuring blood pressure or flow, for example a Doppler ultrasound sensor system, or a sensor for measuring hematocrit (HCT) levels.
  • Alternatively sensor 5 may be a biosensor, for example, comprising an Immobilized biocatalyst, enzyme, immunoglobulin, bacterial, mammalian or plant tissue, cell and/or subcellular fraction of a cell. For example, the tip of a biosensor may comprise a mitochondrial fraction of a cell, thereby providing the sensor with a specific biocatalytic activity.
  • Sensor 5 may be based on potentiometric technology or fiber optic technology. For example, the sensor may comprise a potentiometric or fiber optic transducer. An optical sensor may be based on either an absorbance or fluorescence measurement and may include an UV, a visible or an IR light source.
  • Sensor 5 may be used to detect naturally detectable properties representative of one or more characteristics, e.g., chemical, physical or physiological, of a patients bodily tissues or fluids. For example, naturally detectable properties of patients bodily tissues or fluids may include pH, fluid, flow, electrical current, temperature pressure, components of metabolic processes, chemical concentrations, for example, the absence or presence of specific peptides, proteins, enzymes, gases, ions, etc.
  • Sensor 5 may include one or more imaging systems, camera systems operating in UV, visible, or IR range; electrical sensors; voltage sensors; current sensors; piezoelectric sensors; electromagnetic interference (EMI) sensors; photographic plates, polymer-metal sensors; charge-coupled devices (CCDs); photo diode arrays; chemical sensors, electrochemical sensors; pressure sensors, sound wave sensors; magnetic sensors; UV light sensors; visible light sensors; IR light sensors; radiation sensors; flow sensors; temperature sensors; or any other appropriate or suitable sensor. Sensor 5 may be a continuous, in-line monitoring system or it may be attached to an extracorporeal device.
  • In one embodiment of the invention, sensor 5 may be a cerebral blood flow sensor, in which case, the sensor may be placed in any suitable manner for sensing cerebral blood flow. For example, sensor 5 may be inserted between the skull and the dura of the brain. Alternatively, sensor 5 may be placed in the patients neck. For example, at least a portion of sensor 5 may be placed in an artery, such as the carotid artery. Such a placement would allow measurement of blood as it flows to the brain. Alternatively, sensor 5 may be placed in a vein, such as the jugular vein. This placement would allow measurement of blood as it flows from the brain.
  • In the case of blood oxygen saturation sensing, a certain level of oxygen generally remains in the blood as it flows from the brain. This level may be established by measuring the patients oxygen prior to surgery. If blood measured by sensor 5 in the vein has oxygen below the established level, the brain is consuming all or most of the oxygen flowing to it and probably requires additional oxygen. Other suitable placements of sensor 5 may be possible. Sensor 5 may be used to alert a surgeon to changes in the patients circulatory, system.
  • System 100 may also include a nerve stimulator 10. In one embodiment, the nerve stimulator 10 may be used to electrically manipulate cardiac rhythm by stimulating the vagus nerve. This vagal stimulation may produce asystole (slowing or stopping of the hearts beating.) Once this induced asystole is stopped, i.e. once the vagal stimulation is stopped, the heart may be allowed to return to its usual cardiac rhythm. Alternatively, the heart may be paced with an electrical pacing system, thereby maintaining a normal cardiaic output. Vagal stimulation, alone or in combination with electrical pacing, may be used selectively and intermittently to allow a surgeon to perform a medical procedure during intermittent periods of asystole.
  • It is known that stimulation of the vagus nerve can reduce the sinus rate, as well as prolong AV conduction time or if stimulation energies are high enough, induce AV node block. Use of vagal nerve stimulation to treat supraventricular arrhythmias and angina pectoris is disclosed in the article “Vagal Tuning” by Bilgutay et al., Journal of Thoracic and Cardiovascular Surgery, Vol. 56, No. 1, July, 1968, pp. 71-82. It is also known that stimulation of the carotid sinus nerve produces a similar result, as disclosed in the article “Carotid Sinus Nerve Stimulation in the Treatment of Angina. Pectoris and Supraventricular Tachycardia” by Braunwald et al., published in California Medicine, Vol. 112, pp. 41-50, March, 1970.
  • As set forth in “Functional Anatomy of the Cardiac Efferent Innervation” by Randall et al., in Neurocardiology, edited by Kulbertus et al, Futura Publishing Co., 1988, direct surgical excision of the fat pad associated with the SA node affects the functioning of the SA node without Significantly affecting the AV node. Similarly, excision of the fat pad associated with the AV node affects functioning of the AV node without significantly affecting the SA node.
  • As set forth in the article “Parasympathetic Postganglionic Pathways to the Sinoatrial Node”, Bluemel et al., Am. J. Physiol. 259, (Heart Circ. Physiol. 28). H1504-H1511, 1990, stimulation of the fat pad associated with the SA node results in slowing of the sinus rate without the accompanying prolongation of AV conduction time which normally results from vagal nerve stimulation. The article also indicates that stimulation of the fat pad associated with the AV node is believed to produce corresponding effects limited to the AV node, i.e., extension of the AV conduction time without concurrent slowing of the sinus rate.
  • As set forth in the article “Neural Effects on Sinus Rate and Atrial Ventricular Conduction Produced by Electrical Stimulation From a Transvenous Electrode Catheter in the Canine Right Pulmonary Artery” by Cooper et al., published in Circulation Research, Vol. 46, No. 1, January, 1980, pp. 48-57, the fat pads associated with both the AV node and the SA node may be stimulated by means of electrodes located in the right pulmonary artery. The results obtained include-both a depression of the sinus rate and a prolongation of the AV conduction time in response to continuous stimulation at 2-80 Hz at up to 50 ma.
  • Generally in healthy individuals, the SA node functions as the pacemaker. Normal heart rhythm associated with the SA node is typically referred to as sinus rhythm. When the SA node fails, the AV node generally takes over creating a heart rate of approximately 35 to 60 beats per minute. Heart rhythm associated with the AV node is typically referred to as nodal rhythm. When the AV node itself is blocked or injured, a new seven slower pacemaker site may form at the junction of the AV node and the His bundle. Heart rhythm associated with this junction is typically referred to as junctional, escape rhythm. When this junction site is inhibited, the Purkinje fibers in the His bundle or below may act as a pacemaker creating a heart rate of approximately 30 beats per minute. Heart rhythm associated with the Purkinje fibers is typically referred to as idioventricular rhythm.
  • In one embodiment of the present invention, nerve stimulator 10 may be used to electrically manipulate cardiac rhythm by stimulating the carotid sinus nerve, the fat pad associated with the SA node, the fat pad associated with the AV node, the junction of the AV node and the His bundle and/or the Purkinje fibers.
  • In one embodiment of the present invention, nerve stimulator 10 is used alone or in combination with other heart rate inhibiting agents to temporarily stop or slow the beating heart, thereby eliminating or reducing heart motion and/or blood flow during a medical procedure. For example, the present invention may be used to eliminate or reduce motion in the anastomosis field during CABG Procedures such that a facilitated anastomosis procedure may be performed; safely and effectively. The number of occasions that the vagal nerve may be stimulated depends on the type of medical procedure to be performed. Likewise, the type of medical procedure to be performed will dictate the duration of the individual electrical stimulations.
  • Nerve stimulator 10 may be powered by AC current, DC current or it may be battery powered either by a disposable or rechargeable battery. Nerve stimulator 10 may be configured to synchronize activation and deactivation of breathing regulator 40 with vagal stimulation, thereby minimizing or eliminating unwanted heart and chest motion associated with the patients breathing. Nerve stimulator 10 may comprise a surgeon controlled switch box. A switch may be incorporated in or on one of the surgeons instruments, such as surgical site retractor, or any other location easily and quickly accessed by the surgeon for regulation of the nerve stimulator by the surgeon. The switch may be, for example, a hand switch, a footswitch, or a voice-activated switch comprising voice-recognition technologies.
  • A visual and/or audible signal used to alert a surgeon to the completion or resumption of vagal nerve stimulation may be incorporated into nerve stimulator 10. For example, a beeping tone or flashing light that increases in frequency as the nerve stimulation period should end or begin may be used.
  • Nerve stimulator 10 may be slaved to cardiac stimulator 20 or cardiac stimulator 20 may be slaved to nerve-stimulator 10. For example, the output of cardiac stimulator 20 may be off whenever the output of nerve stimulator 10 is on. Software controlling cardiac stimulator 20 may be designed to automatically commence cardiac pacing if the heart does not resume beating within a pre-determined interval after cessation of vagal nerve stimulation. In addition, the software controlling nerve stimulator 10 may be designed to automatically stop vagal nerve stimulation if the heart has been stopped for to long. For example, a predetermined time interval may be set to automatically stop vagal stimulation. In one embodiment of the invention, if sensor 5 of the present invention indicates that not enough blood is flowing to the brain, vagal stimulation may be stopped, thereby allowing the heart to beat again.
  • In another embodiment it may be necessary to use cardiac stimulator 20 to actively stimulate the heart into beating again. For example in one embodiment of the present invention, sensor 5 may indicate that not enough, blood is flowing to the brain causing nerve stimulator 10 to be automatically turned off and cardiac stimulator 20 to be automatically turned on. Alternatively, the surgeon may turn on cardiac stimulator 20 to begin stimulation.
  • Just like nerve stimulator 10, cardiac stimulator 20 may be intermittently stopped and, started to allows the surgeon to perform individual steps of a medical procedure.
  • Cardiac stimulator 20 may be a conventional ventricular demand pacer or dual chamber (atrial-ventricular) pacer. Cardiac stimulator 20 may be powered by AC current, DC current or it may be battery powered either by a disposable or re-chargeable battery. Cardiac stimulator 20 may be configured to synchronize activation and deactivation of breathing regulator 40 with pacing, thereby minimizing or eliminating unwanted heart and chest motion associated with the patients breathing.
  • Cardiac stimulator 20 may be any conventional pacing device suitable for ventricular demand pacing and having leads electrically coupled to a switch box. Cardiac stimulator 20 may be combined in a single unit with a switch box. A switch may be incorporated in or on one of the surgeon's instruments, such as surgical site retractor, or any other location easily and quickly accessed by the surgeon for regulation of the cardiac stimulator by the surgeon. The switch may be, for example, a hand switch, a foot-switch, or a voice-activated switch comprising voice-recognition technologies. A single switch may be used to regulate both cardiac stimulator 20 and nerve stimulator 10.
  • A visual and/or audible signal used to prepare a surgeon for the resumption of pacing may be incorporated into cardiac stimulator 20. For example, a beeping tone or flashing light that increases in frequency as the pacing period ends may be used. A single signaling method or device may be used for both cardiac stimulator 20 and nerve stimulator 10.
  • Sensor 5, nerve stimulator 10 and/or cardiac stimulator 20 may be slaved to a robotic system or a robotic system may be slaved to sensor 5, nerve stimulator 10 and/or cardiac stimulator 20. Breathing regulator 40 and other components may also be slaved to such a system. Computer and voice-controlled robotic systems that position and maneuver endoscopes and/or other surgical instruments for performing microsurgical procedures such as anastomoses through small incisions may be used by a surgeon to perform precise and delicate maneuvers. These robotic systems may allow a surgeon to perform a variety of microsurgical procedures-including endoscopic CABG. Endoscopic CABG may allow multiple occluded coronary arteries to be bypassed without a thoracotomy or mini-thoracotomy. Heart valve repair and replacement may also be other surgical applications for these robotic systems. In general, robotic systems may include head-mounted displays, which integrate 3-D visualization of surgical anatomy and related diagnostic and monitoring data, miniature high resolution 2-D and 3-D digital cameras, a computer, a high power light source and a standard video monitor.
  • System 100 may also include a breathing regulator 40. In one embodiment, the breathing regulator 40 may be used to stimulate the phrenic nerve in order to provide a diaphragmatic pacemaker. Breathing regulator 40 may comprise one or more electrodes for supplying electrical current to the phrenic nerve to control breathing during vagal and/or cardiac stimulation and/or destimulation. Electrodes used to stimulate the phrenic nerve may be, for example, non-invasive, e.g., clips, or invasive, e.g., needles or probes. The application of an electrical stimulus to the phrenic nerve may include, but is not limited to bipolar and/or monopolar techniques. Different electrode positions are accessible through various access openings, for example, in the cervical or thorax regions. Nerve stimulation electrodes may be positioned through a thoracotomy, sternotomy, endoscopically through a percutaneous port, through a stab wound or puncture, through a small incision, placed on the skin or in combinations thereof. The present invention may include various electrodes, catheters and electrode catheters suitable for phrenic nerve stimulation to control breathing.
  • Phrenic nerve stimulation electrodes may be intravascular, patch-type, balloon-type, basket-type, umbrella-type, tape-type, cuff-type, suction-type, screwy-type, barb-type, bipolar, monopolar, metal, wire, endotracheal, endoesophageal intravascular, transcutaneous or intracutaneous electrodes. Guided or steerable catheter devices comprising electrodes may be used alone- or in combination with the nerve stimulation electrodes. For example, a catheter comprising one or more wire, metal strips or metal foil electrodes or electrode arrays may be used. The catheter may comprise, for example, a balloon, which may be inflated with air or liquid to press the electrodes firmly against a vessel wall that lays adjacent the phrenic nerve.
  • Phrenic nerve stimulation electrodes may be oriented in any fashion along the catheter device, including longitudinally or transversely. Various techniques such as ultrasound, fluoroscopy and echocardiography may be used to facilitate positioning of the electrodes. If desired or necessary, avoidance of obstruction of blood flow may be achieved with notched catheter designs or with catheters which incorporate one or more tunnels or passageways.
  • In another embodiment, breathing regulator 40 may comprise a connector, which interfaces with a patients respirator, and sends a logic signal to activate or deactivate the respirator to control breathing during vagal and/or cardiac stimulation and/or destimulation.
  • FIG. 2 shows one embodiment of the present invention at 200. In this embodiment, the elements named above may be combined or connected to a control unit along with other components. Unit 200 may be used to coordinate the various elements.
  • Unit 200 may incorporate a controller as described above or any suitable processor 230. For example, the processor may process sensed blood information from sensor 205. The controller may store and/or process such information before, during and/or after a medical procedure. For example, the patients oxygen concentration or blood pressure may be sensed, stored and processed prior to and during surgery.
  • Unit 200 may also incorporate a nerve stimulator. For example, FIG. 2 shows an electrode for nerve stimulation at 210. Electrodes used to stimulate a nerve such as the vagal nerve may be, for example, non-invasive, e.g., clips, or invasive, e.g., needles or probes. The application of an electrical stimulus to the right or left vagal nerve may include, but is not limited to bipolar and/or monopolar techniques. Different electrode positions are accessible through various access openings, for example, in the cervical or thorax regions. Nerve stimulation electrodes 210 may be positioned through a thoracotomy, sternotomy, endoscopically through a percutaneous port, through a stab wound or puncture, through a small incision in the neck or chest, through the internal jugular vein, the esophagus, the trachea, placed on the skin or in combinations thereof. Electrical stimulation may be carried out on the right vagal nerve, the left vagal nerve or to both nerves simultaneously or sequentially. The present invention may include various electrodes, catheters and electrode catheters suitable for vagal nerve stimulation to temporarily stop or slow the beating heart alone or in combination with other heart rate inhibiting agents.
  • Nerve stimulation electrodes 210 may be endotracheal, endoesophageal, intravascular, transcutaneous, intracutaneous, patch-type, balloon-type, cuff-type; basket-type, umbrella-type, tape-type, screw-type, barb-type, metal, wire, or suction-type electrodes. Guided or steerable catheter devices comprising electrodes may be used alone or in combination with the nerve stimulation electrodes 210. For example, a catheter comprising one or more wire, metal strips or metal foil electrodes or electrode arrays maybe inserted into the internal jugular vein to make electrical contact with the wall of the internal jugular vein, and thus stimulate the vagal nerve adjacent to the internal jugular vein. Access to the internal jugular vein may be via, for example, the right atrium, the right atrial appendage, the inferior vena cava or the superior vena cava. The catheter may comprise, for example, a balloon, which may be inflated with air or liquid to press the electrodes firmly against the vessel wall. Similar techniques may be performed by insertion of a catheter type device into the trachea or esophagus. Additionally tracheal tubes and esophageal tubes comprising electrodes may be used.
  • Nerve stimulation electrodes 210 may be oriented in any fashion along the catheter device, including longitudinally or transversely. Various techniques such as ultrasound, fluoroscopy and echocardiography may be used to facilitate positioning of the electrodes. If desired or necessary, avoidance of obstruction of blood flow may be achieved with notched catheter designs or with catheters which incorporate one or more tunnels or passageways.
  • In one embodiment of the present invention the location of the electrodes 210 is chosen to elicit maximum bradycardia effectiveness while minimizing current spread to adjacent tissues and vessels and to prevent the induction of post stimulation tachycardia. Furthermore, a non-conductive material such as configurations to shield them from the surrounding tissues and vessels, while exposing their confronting edges and surfaces for positive contact with the vagal nerve or selected tissues.
  • Unit 200 may also incorporate a cardiac stimulator. For example, FIG. 2 shows a electrode for stimulation of the heart at 220. Cardiac electrodes 220 used to stimulate the heart may be, for example, non-invasive, e.g., clips, or invasive, e.g. needles or probes. Electrodes 220 may be positioned through a thoracotomy, sternotomy, endoscopically through a peutaneous port, through a stab wound or puncture, through a small incision in the chest, placed on the chest or in combinations thereof. The present invention may also use various electrodes, catheters and electrode catheters and to pacing the heart, e.g., epicardial, patch-type, intravascular, balloon-type, basket-type, umbrella-type tape-type electrodes, suction-type, pacing electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes, Guided or steerable catheter devices comprising electrodes may be used alone or in combination with the electrodes. Controller 230 may be used to gather information from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220. Controller 230 may also be used to control the stimulation levels and stimulation duration from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220. Controller 230 may also gather and process information from sensor 205. This information may be used to adjust-stimulation levels and stimulation times from nerve stimulation electrodes 210 and cardiac stimulation electrodes 220.
  • Unit 200 may incorporate one or more switches to facilitate regulation of the various components by the surgeon. One example of such a switch is shown as foot pedal 250. The switch may also be, for example, a hand switch, or a voice-activated switch comprising voice-recognition technologies. The switch may be incorporated in or on one of the surgeons instruments, such as surgical site retractor, or any other location easily and quickly accessed by the surgeon. Unit 200 may also include a display 260. Unit 200 may also include other means of indicating the status of various components to the surgeon such as a numerical display, gauges, a monitor display or audio feedback. Unit 200 may also include one or more visual and/or audible signals used to prepare a surgeon for the start or stop of nerve stimulation and/or cardiac stimulation.
  • FIG. 3 shows a flow diagram of one embodiment of the present invention. The patient is prepared for a medical procedure at 500. Once the patient is prepared, the initial state of cerebral blood circulation is measured (Block 505). Such measurements may include for example blood flow, oxygen concentration, carbon dioxide concentration, etc. The initial state of cerebral blood circulation is then used as a gauge to compare with the state of cerebral blood circulation during the procedure.
  • At Block 510, a nerve that controls the beating of the heart is stimulated. Such a nerve may be for example a vagal nerve. At Block 510, one or more of a variety of pharmacological agents or drugs may be delivered. These drugs may produce reversible asystole of a heart while maintaining the ability of the heart to be electrically paced.
  • A variety of pharmacological agents or drugs may also be delivered at other times during the procedure 500. These drugs may also produce reversible asystole of a heart while maintaining the ability of the heart to be electrically paced. Other drugs may be administered for a variety of functions and purposes as described below. Drugs may be delivered at any appropriate time during the medical procedure, for example, at the beginning of the procedure, intermittently during the procedure, continuously during the procedure or following the procedure.
  • Drugs, drug formulations or compositions suitable for administration to a patient during a medical procedure may include a pharmaceutically acceptable carrier or solution in an appropriate dosage. There are a number of pharmaceutically acceptable carriers that may be used for delivery of various drugs, for example, via direct injection, oral delivery suppository delivery, transdermal delivery, epicardial delivery and/or inhalation delivery. Pharmaceutically acceptable carriers include a number of solutions, preferably sterile, for example, water, saline. Ringers solution and/or sugar solutions such as dextrose in water or saline. Other possible carriers that may be used include sodium citrate, citric acid, amino acids, lactate, mannitol, maltose, glycerol, sucrose, ammonium chloride, sodium chloride, potassium chloride, calcium chloride, sodium lactate, and/or sodium bicarbonate. Carrier solutions may or may not be buffered.
  • Drug formulations or compositions may include antioxidants or preservatives such as ascorbic acid. They may also be in a pharmaceutically acceptable form for parenteral administration, for example to the cardiovascular system, or directly to the heart, such as intracoronary infusion or injection. Drug formulations or compositions may comprise agents that provide a synergistic effect when administered together. A synergistic effect between two or more drugs or agents may reduce the amount that normally is required for therapeutic delivery of an individual drug or agent. Two or more drugs may be administered, for example, sequentially or simultaneously. Drugs may be administered via one or more bolus injections and/or infusions or combinations thereof. The injections and/or infusions may be continuous or intermittent. Drugs may be administered, for example, systemically or locally, for example, to the heart, to a coronary artery and/or vein, to a pulmonary artery and/or vein, to the right atrium and/or ventricle, to the left atrium and/or ventricle to the aorta, to the AV node, to the SA node, to a nerve and/or to the coronary sinus. Drugs may be administered or delivered via intravenous, intracoronary and/or intraventricular administration in a suitable carrier. Examples of arteries that may be used to deliver drugs to the AV node include the AV node artery, the right coronary artery, the right descending coronary artery, the left coronary artery, the let anterior descending coronary artery and Kugel's artery. Drugs may be delivered systemically, for example, via oral, transdermal, intranasal suppository or inhalation methods. Drugs also may be delivered via a pill, a spray, a cream, an ointment or a medicament formulation.
  • Drugs may be delivered via a drug delivery device that may comprise a catheter, such as a drug delivery catheter or a guide catheter, a patch, such as a transepicardial patch that slowly releases drugs directly into the myocardium, a cannula, a pump and/or a hypodermic needle and syringe assembly. A drug delivery catheter may include an expandable member, e.g., a low-pressure balloon, and a shaft having a distal portion, wherein the expandable member is disposed along the distal portion. A catheter for drug delivery may comprise one or more lumens and may be delivered endovascularly via insertion into a blood vessel, e.g., an artery such as a femoral, radial, subclavian or coronary artery. The catheter can be guided into a desired position using various guidance techniques, e.g., flouroscopic guidance and/or a guiding catheter or guide wire techniques. Drugs may be delivered via an iontophoretic drug delivery device placed on the heart. In general, the delivery of ionized drugs may be enhanced via a small current applied across two electrodes. Positive ions may be introduced into the tissues from the positive pole, or negative ions from the negative pole. The use of iontophoresis may markedly facilitate the transport of certain ionized drug molecules. For example, lidocaine hydrochloride may be applied to the heart via a drug patch comprising the drug. A positive electrode could be placed over the patch and current passed. The negative electrode would contact the heart or other body part at some desired distance point to complete the circuit. One or more of the electrodes may also be used as nerve stimulation electrodes 210 or as cardiac stimulation electrodes 220.
  • The two divisions of the autonomic nervous system that regulate the heart have opposite functions. First, the adrenergic or sympathetic nervous system increases heart rate by releasing epinephrine and norepinephrine. Second, the parasympathetic system also known as the cholinergic nervous system or the vagal nervous system decreases heart rate by releasing acetylcholine. Catecholamines such as norepinephrine (also called noradrenaline) and epinephrine (also called adrenaline) are agonists for beta-adrenergic receptors. An agonist is a stimulant biomolecule or agent that binds to a receptor.
  • Beta-adrenergic receptor blocking agents compete with beta-adrenergic receptor stimulating agents for available beta-receptor sites. When access to beta-receptor sites are blocked by receptor blocking agents, also known as beta-adrenergic blockade, the chronotropic or heart rate, inotropic or contractility, and vasodilator responses to receptor stimulating agents are decreased proportionately. Therefore, beta-adrenergic receptor blocking agents are agents that are capable of blocking beta-adrenergic receptor sites.
  • Since beta-adrenergic receptors are concerned with contractility and heart rate, stimulation of beta-adrenergic receptors, in general, increases heart rate, the contractility of the heart and the rate of conductor of electrical impulses through the AV node and the conduction system.
  • Drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized (synthetic analogues) beta-adrenergic receptor blocking agents. Beta-adrenergic receptor or □-adrenegic blocking agents are also known as beta-blockers or □-blockers and as class II antiarrhythmics.
  • The term “beta-blocker” appearing herein may refer to one or more agents that antagonize the effects of beta-stimulating catecholamines by blocking the catecholamines ines from binding to the beta-receptors. Examples of beta-blockers include, but are not limited to a acebutolol, alprenolol, atenolol, betantolol, betaxolol, becantolol, bisoprolol, carterolol, celiprblol, chlorthalidone, esmolol, labetalol, metoprolol, nadolol, penbutolol, pindolol, propranolol, oxprenolol, sotalol, teratolo, timolol and combinations, mixtures and salts thereof.
  • The effects of administered beta-blockers may be reversed by administration of beta-receptor agonists, e.g., dobutamine or isoproterenol.
  • The parasympathetic or cholinergic system participates in control of heart rate via the sinoatrial (SA) node, where it reduces heart rate. Other cholinergic effects include inhibition of the AV node and an inhibitory effect on contractile force. The cholinergic system acts through the vagal nerve to release acetylcholine, which, in turn, stimulates cholinergic receptors. Cholinergic receptors are also known as muscarinic receptors. Stimulation of the cholinergic receptors decreases the formation of CAMP. Stimulation of cholinergic receptors generally has an opposite effect on heart rate compared to stimulation of beta-adrenergic receptors. For example, beta-adrenergic stimulation increases heart rate, whereas cholinergic stimulation decreases it. When vagal tone is high and adrenergic tone is low, there is a marked slowing, of the heart (sinus bradycardia). Acetylcholine effectively reduces the amplitude, rate of increase and duration of the SA node action potential. During vagal nerve stimulation, the SA node does not arrest. Rather, pacemaker function may shift to cells that fire at a slower rate. In addition, acetylcholine may help open certain potassium channels thereby creating an outward flow of potassium ions and hyperpolarization. Acetylcholine also slows conduction through the AV node.
  • Drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized (synthetic analogues) cholinergic agent. The term “cholinergic agent” appearing herein may refer to one or more cholinergic receptor modulators, or agonists. Examples of cholinergic agents include, but are not limited to, acetylcholine, carbachol (carbamyl choline chloride), bethanechol, methacholine, arecoline, norarecoline and combinations, mixtures and/or salts thereof.
  • Drugs, drug formulations and/or drug compositons that may be used according to this invention may include any naturally occurring or chemically synthesized cholinesterase inhibitor. The term “cholinesterase inhibitor” appearing herein may refer to one or more agents that prolong the action of acetylcholine by inhibiting its destruction or hydrolysis by cholinesterase. Cholinesterase inhibitors are also known as acetylcholinesterase inhibitors. Examples of cholinesterase inhibitors include, but are not limited to, edrophonium, neostigmine, neostigmine methylsulfate; pyridostigmine, tacrine and combinations, mixtures and/or salts thereof.
  • There are ion-selective channels within certain cell membranes. These ion selective channels include calcium channels, sodium channels and/or potassium channels. Therefore, other drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized calcium channel blocker. Calcium channel blockers inhibit the inward flux of calcium ions across cell membranes of arterial smooth muscle cells and myocardial cells. Therefore, the term “calcium channel blocker” appearing herein may refer to one or more agents that inhibit or block the flow of calcium ions across a cell membrane. The calcium channel is generally concerned with the triggering of the contractile cycle. Calcium channel, blockers are also known as calcium ion influx inhibitors, slow channel blockers, calcium ion antagonists, calcium channel antagonist drugs and as class IV antiarrhythmics. A commonly used calcium channel blocker is verapamil.
  • Administration of a calcium channel blocker, e.g., verapamil, generally prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner, since the electrical activity through the AV node depends significantly upon the influx of calcium ions through the slow channel. A calcium channel blocker has the ability to slow a patients heart rate, as well as produce AV block. Examples of calcium channel blockers include, but are not limited to, amiloride, amlodipine, bepridil, diltiazem, felodipine, isradipine, mibefradil, nicardipine, nifedipine (dihydropyridines), nickel, nimodinpine, nisoldipine, nitric oxide (NO), norverapamil and veraparhil and combinations, mixtures and/or salts thereof. Verapamil and diltiazem are very effective at inhibiting the AV node, whereas drugs of the nifedipine family have a lesser inhibitory effect on the AV node. Nitric oxide (NO) indirectly promotes calcium channel closure. NO may be used to inhibit contraction. NO may also be used to inhibit sympathetic outflow, lessen the release of norepinephrine, cause vasodilation, decrease heart rate and decrease contractility. In the SA node, cholinergic stimulation leads to formation of NO.
  • Other drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized sodium channel blocker. Sodium channel blockers are also known as sodium channel inhibitors, sodium channel blocking agents, rapid channel blockers or rapid channel inhibitors. Antiarrhythmic agents that inhibit or block the sodium channel are known as class I antiarrhythmics, examples include, but are not limited to, quinidine and quinidine-like agents, lidocaine and lidocaine-like agents, tetrodotoxin, encainide, flecainid and combinatons, mixtures and/or salts thereof. Therefore, the term “sodium channel blocker” appearing herein may refer to one or more agents that inhibit or block the flow of sodium ions across a cell membrane or remove the potential difference across a cell membrane. For example, the sodium channel may also be totally inhibited by increasing the extracellular potassium levels to depolarizing hyperkalemic values, which remove the potential difference across the cell membrane. The result is inhibition of cardiac contraction with cardiac arrest (cardioplegia). The opening of the sodium-channel (influx of sodium) is for swift conduction of the electrical impulse throughout the heart.
  • Other drugs, drug formulations and/or drug compositions that may be used according to this invention may include any naturally occurring or chemically synthesized potassium channel agent. The term “potassium channel agent” appearing herein may refer to one or more agents that impact the flow of potassium ions across the cell membrane. There are two major types of potassium channels. The first type of channel is voltage-gated and the second type is ligand-gated. Acetylcholine-activated potassium channels, which are ligand-gated channels, open in response to vagal stimulation and the release of acetylcholine. Opening of the potassium channel causes hyperpolarization, which decreases the rate at which the activation threshold is reached. Adenosine is one example of a potassium channel opener. Adenosine slows conduction through the AV node. Adenosine, a breakdown product of adenosine triphosphate inhibits the AV node and atria. In, atrial tissue, adenosine causes the shortening of the action potential duration and causes hyperpolarization. In the AV node, adenosine has similar effects and also decreases the action potential amplitude and the rate of increase of the action potential. Adenosine is also a direct vasodilator by its actions on the adenosine receptor on vascular smooth muscle cells. In addition, adenosine acts as a negative neuromodulator, thereby inhibiting release of norepinephrine. Class III antiarrhythmic agents also known as potassium channel inhibitors lengthen the action potential duration and refractoriness by blocking the outward potassium channel to prolong the action potential. Amiodarone and d-sotalol are both examples of class III antiarrhythmic agents.
  • Potassium is the most common component in cardioplegic solutions. High extracellular potassium levels reduce the membrane resting potential. Opening of the sodium channel, which normally allows rapid sodium influx during the upstroke of the action potential, is therefore inactivated because of a reduction in the membrane resting potential. The present invention may be combined with conventional CPB, the induced asystole as described by this invention may serve as a substitute for conventional cardioplegic arrest. For example, the combination of drugs and vagal stimulation may be used as a cardioplegic agent in a variety of medical procedures.
  • Drugs, drug formulations and/or drug compositions that may be used during according to this invention may comprise one or more of any naturally occurring or chemically synthesized beta-blocker, cholinergic agent, cholinesterase inhibitor, calcium channel blocker, sodium channel blocker, potassium channel agent, adenosine, adenosine receptor agonist, adenosine deaminase inhibitor, dipyridamole, monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, bradykinin agents, serotoninergic agonist, antiarrythmic agents, cardiac glycosides, local anesthetics and combinations or mixtures thereof. Digitalis and digoxin both inhibit the sodium pump. Digitalis is a natural inotrope derived from plant material, while digoxin is a synthesized inotrope. Dipyridamole inhibits adenosine deaminase, which breaks down adenosine. Drugs, drug formulations and/or drug compositions capable of reversibly suppressing autonomous electrical conduction at the SA and/or AV node, while still allowing the heart to be electrically paced to maintain cardiac output may be used according to this invention.
  • In one embodiment, thee cardiac asystole produced in accordance with the resent invention is reversible e.g., chemically such as by the administration of atropine or by natural forces. Beta-adrenergic stimulation or administration of calcium solutions may be used to reverse the effects of a calcium channel blocker such as verapamil. Agents that promote heart rate and/or contraction may be used in a preferred embodiment of the present invention. For example, dopamine, a natural catbcliplamine, is known to increase contractility. Positive inotropes are agents that specifically increase the force of contraction of the heart. Glucagon, a naturally occurring hormone, is known to increase heart rate and contractility. Glucagon may be used to reverse the effects of a beta-blocker since its effects bypass the beta receptor. Forskolin is known to increase heart rate and contractility. As mentioned earlier epinephrine and norepiriephrine naturally increase heart rate and contractility. Thyroid hormone, phosphodiesterase inhibitors and prostacyclin, a prostaglandin are also known, to increase heart rate and contractility. In addition, methylxanthines are known to prevent adenosine from interacting with its cell receptors.
  • Typically, vagal nerve stimulation prevents the heart from contracting. This non-contraction must then be followed by periods. Without vagal nerve stimulation during which the heart is allowed to contract, and blood flow is restored throughout the body. At block 517, the state of cerebral blood circulation may be monitored. This monitoring may occur at specific points during the procedure, for example, as shown at block 517. Alternatively, monitoring may occur continuously. If cerebral blood circulation is sufficient, then all or a portion of the medical procedure may be carried out (Block 520). However, if the state of cerebral blood circulation is not sufficient, then a signal may indicate that the state of blood circulation to the brain is insufficient. If the sensor indicates that the state of blood circulation is insufficient, the surgeon may proceed to block 530, where the nerve stimulation is ceased an the heart is allowed to contract. The cardiac stimulator may be used to cause the heart to contract. Alternatively, unit 200 may automatically proceed to Block 530 to cease nerve stimulation. In addition, Unit 200 may automatically begin cardiac stimulation.
  • The state of cerebral blood circulation sensed by sensor 5 may be communicated to the surgeon by a number of suitable means. For example, the ambient blood flow may be indicated on a display or monitor. A visual or audio signal may indicate when the level of cerebral blood flow reaches a certain level, e.g. when blood flow is insufficient. Alternatively, the system of the present invention may “lock” the controls of the vagal stimulator in an “off” state when cerebral blood flow reaches a predetermined condition, thereby indicating that blood flow is insufficient. The system may then release the controls when the state of cerebral blood circulation sensed by the sensor is again sufficient.
  • Additionally, the amount of vagal nerve stimulation used may be adjusted based on the output of the sensor 5. For example, the level of stimulation may be lowered or the duration of stimulation may be lowered if the sensor indicates that cerebral blood circulation at 517 is insufficient. This adjustment may be automatic or may be controlled by the surgeon.
  • At Block 520, a medical procedure may be performed or begun. Such a procedure may be for example surgery on the heart. Alternatively, the procedure may be surgery performed on another organ of the body.
  • The term “medical procedure” may mean any one or more medical or surgical procedures such as, for example cardiac surgery, performed with or without cardiopulmonary bypass (CPB) circuits, heart valve repair, heart valve replacement, MAZE procedures, transmyocardial revascularization (TMR), CABG procedures, anastomosis procedures, non-surgical procedures, fluoroscpic procedures, beating heart surgery, vascular surgery, neurosurgery, brain surgery, electrophysiology procedures diagnostic and therapeutic procedures, ablation procedures, ablation of arrhythmias, endovascular procedures, treatment of the liver, spleen, heart, lungs, and major blood vessels, aneurysm repair, imaging procedures of the heart and great vessels, CAT scans or MRI procedures, pharmacological therapies, drug delivery procedures, gene therapies, cellular therapies, cancer therapies, radiation therapies, genetic, cellular, tissue and/or organ manipulation or transplantation procedures, coronary angioplasty procedures, placement or delivery of coated or noncoated stents, atherectomy procedures, atherosclerotic plaque manipulation and/or removal procedures, procedures where bleeding needs to be precisely controlled, procedures that require precise control of cardiac motion and/or bleeding.
  • When the medical procedure comprises one or more medical devices, e.g., coated stents, these devices may be coated with one or more radioactive materials and/or biological agents such as, for example, an anticoagulant agent, an antithrombotic agent, a clotting agent, a platelet agent, an anti-inflammatory agent an antibody, an antigen, an immunoglobulin, a defense agent, an enzyme, a hormone, a growth factor, a neurotransmitter, a cytokine, a blood agent, a regulatory agent, a transport agent, a fibrous agent, a protein, a peptide, a proteoglycan, a toxin, an antibiotic agent, an antibacterial agent, an antimicrobial agent, a bacterial agent or component, hyaluronic acid a polysaccharide, a carbohydrate, a fatty acid, a catalyst, a drug, a vitamin, a DNA segment, a RNA segment, a nucleic acid, a lectin, an antiviral agent, a viral agent or component, a genetic agent, a ligand and a dye (which acts as a biological ligand). Biological agents may be found in nature (naturally occurring) or may be chemically synthesized.
  • The medical procedure may be non-invasive, minimally invasive and/or invasive. The medical procedure-may entail a port-access approach, a partially or totally endoscopic approach, a sternotomy approach or a thoracotomy approach. The medical procedure may include the use of various mechanical stabilization devices or techniques as well as various robotic or imaging systems.
  • In one method, the heart may be temporarily slowed or intermittently stopped for short periods of time to permit the surgeon to accomplish the required surgical task and yet still allow the heart itself to supply blood circulation to the body. For example, stimulation of the vagus nerve in order to temporarily and intermittently slow or stop the heart is described in U.S. Pat. No. 6,006,134 entitled “Method and Device for Electronically Controlling the Beating of a Heart Using Venous Electrical Stimulation of Nerve Fibers”, Dec. 21, 1999, to Hill and Junkman. This patent is assigned to Medtronic, Inc. and is incorporated herein by reference.
  • During this medical procedure, the state of cerebral blood circulation may be monitored constantly or intermittently as described above. An assessment, for example, of the amount of blood flowing to the brain may again be taken at block 525. If the state of cerebral blood circulation is sufficient the physician may continue with the medical procedure that is in progress. However, if the state of cerebral blood circulation is not sufficient, then the sensor 5 may indicate that blood circulation to the brain is insufficient. If the sensor indicates that blood circulation is insufficient, the surgeon may proceed to Block 530, where the nerve stimulation is ceased. The heart will therefore be allowed to contract and thus blood will again be allowed to flow to the brain and vital organs. The cardiac stimulator maybe used to cause the heart to contract. Alternatively, unit 200 may automatically proceed to Block 530 to cease nerve stimulation. In addition, Unit 200 may automatically begin cardiac stimulation. Additionally the amount of vagal nerve stimulation used may be adjusted based on the output of the sensor 5. For example, the level of stimulation may be lowered or the duration of stimulation may be lowered if the sensor indicates that cerebral blood circulation at 525 is insufficient.
  • After a time, the medical procedure or one phase of the procedure is completed at 520. After some phase of the medical procedure is performed, cardiac contractions are allowed to occur (Block 530). Cardiac contractions may need to occur intermittently during the procedure to ensure adequate blood flow. In one embodiment, the stimulation from the nerve stimulator 10 is stopped or slowed enough to allow the heart to contract. For example, the vagal nerve stimulation is removed, thereby allowing cardiac contractions to occur.
  • In another embodiment, the heart may be stimulated to ensure that cardiac contractions occur (Block 535). For example, cardiac stimulator 20 may be used to apply pacing pulses to the heart to encourage the heart to contract normally. In particular, the pacing pulses may be applied to the ventricle as is well known in the field. Additionally, the amount of cardiac stimulation used may be adjusted based on the output of the sensor 5. For example, the level of stimulation may, be increased or the duration of stimulation may be increased if the sensor indicates that cerebral blood circulation at 525 is insufficient.
  • The present invention permits the heart to be stilled or quiescent for selected and controllable periods of time in order to permit a medical procedure to be performed. While such a period of stillness or quiescence is desired, it must not last too long, otherwise insufficient blood and oxygen is delivered to organs. Thus, it is necessary to have the periods when the heart is beating (Blocks 530, 535).
  • The state of cerebral blood circulation, for example, sensed by sensor 5 while the heart is beating may be communicated to the surgeon by a number of suitable means. For example, ambient blood flow may be indicated on a display or monitor. A visual or audio signal may indicate when the level of cerebral blood flow reaches a certain level, e.g. when blood flow is insufficient. Alternatively, the system of the present invention may “lock” the controls of the cardiac stimulator in an “on” state when the state of cerebral blood circulation reaches a predetermined condition, thereby indicating that blood circulation is insufficient. The system may then release the controls when the state of blood circulation sensed by the sensor is again sufficient.
  • If additional medical procedures or additional stages of medical procedures need to be performed, the heart may again be stilled using the methods of stilling the heart described above. Therefore from Block 530 or Block 535, the method may be repeated (as in the loop designated by 540). For example, the heart may again be prevented from contracting by stimulation of the vagal nerve (510). Additional drugs may be delivered or the drugs previously administered may continue to be administered.
  • This cycle may be repeated until the procedure, such as the surgery, is completed. As the cycle continues sensor 5 enables monitoring of the state of blood circulation and, if necessary, appropriate adjustment of nerve stimulation and cardiac stimulation to ensure sufficient blood circulation.
  • For example, the surgical procedure at 520 may require several stitches to be made by the surgeon. The surgeon may stimulate the vagal nerve, at 510 to stop the heart. Then the surgeon may make the first stitch at 520. The surgeon may then reduce or halt stimulation at 530 and allow the heart to contract. The surgeon may also pace the heart at 535. Then at 540, the surgeon may return to 510 to inhibit contractions of the heart. At 520, the surgeon will then make the second stitch. This process may be repeated (the loop designated by 540 may be repeated) until all the required stitches have been made. Meanwhile, the state of blood circulation is monitored continuously or, for example at Blocks 517 and 525 by sensor 5. The procedure may proceed uninterrupted if the state of blood circulation remains sufficient.
  • If required, after the procedure is completed, step 535 may be performed until the heart is beating normally. Step 545 may be continued until, the physician is satisfied that the heart is beating normally and the state of blood circulation has reached an acceptable level.
  • FIG. 4 is a timeline showing the relationship of a sensor, a nerve stimulator and a cardiac stimulator in one embodiment of the present invention.
  • Point 610 indicates a point before the medical procedure has begun. At this point 610, both nerve stimulation and cardiac stimulation are off. At point 610, the heart is beating regularly. The patients state of cerebral blood circulation, for example, may be measured by sensor 5 at point 610. Thus sensor 5 may be turned on at point 610.
  • Then nerve stimulation is turned on to inhibit beating of the heart. During phase 601, the vagal nerve stimulation is on and the cardiac stimulation is off. This is the condition of the two types of stimulation at step 520 described above. In one embodiment, shown in FIG. 3 sensor 5 is on throughout the entire procedure. Alternatively, sensor 5 may be turned on during phase 601 to check the state of cerebral blood circulation (as described at Block 517).
  • Point 611 is a representative point during phase 601. At point 611 the contractions of the heart are stilled or substantially slowed. Also, at point 611, the current state of cerebral blood-circulation may be determined (as described at Blocks 517 and 525). If the state of cerebral blood circulation at point 611 is sufficient, then the medical procedure can proceed (as described at Block 520). However, if the state of cerebral blood circulation is not sufficient at point 611, sensor 5 may provide a signal indicating that the state of cerebral blood circulation is insufficient. The surgeon may then proceed immediately to phase 602. Alternatively, control unit 200 may automatically proceed to phase 602 after providing the signal.
  • Additionally, the amount of vagal stimulation used may be adjusted based on the output of the sensor 5. For example, the level of stimulation may be decreased or the duration of stimulation may be decreased if the sensor indicates that the state of blood circulation, at point 611 is insufficient.
  • During phase 602 the vagal stimulation is turned off (as described at step 530) and the cardiac stimulation may be turned on (as described at 535). Point 612 is a representative point during phase 602. At point 612, the contractions are allowed and/or may be induced. In one embodiment, sensor 5 is still on during phase 602. Alternatively, sensor 5 may be turned on during phase 602 to check the state of blood circulation to the brain.
  • Additionally, the amount of cardiac stimulation used may be adjusted based on the output of the sensor 5. For example, the level of stimulation may be increased or the duration of stimulation may be increased if the sensor indicates that cerebral blood circulation at point 612 is insufficient.
  • During phase 603, the vagal nerve stimulation is again turned on and the cardiac stimulation is turned off. Also, during phase 603, sensor 5 may still be on. The amount or duration of vagal stimulation during phase 603 may be different than the amount or duration of vagal stimulation during phase 601, based on the data gathered from sensor 5 during phase 601. Alternatively, the current state of cerebral blood circulation may again be determined during phase 603 (as described at Block 525). Point 613 is a representative point during phase 603. If the state of blood circulation at point 613 is sufficient, then the medical procedure can proceed (as described in step 520). However, if the state of blood circulation is not sufficient at point 611, sensor 5 may provide a signal indicating that blood circulation is insufficient. The surgeon may then proceed immediately to phase 602. Alternatively control unit 200 may automatically proceed to phase 602 after providing the signal. Additionally, the amount of vagal stimulation used may again be adjusted based on the output of the sensor 5.
  • During phase 604 the vagal stimulation is again turned off and the cardiac stimulation may again be turned on. The amount or duration of cardiac stimulation during phase 604 may be different than the amount or duration of cardiac stimulation during phase 602, based on the data gathered from sensor 5 during the previous phases.
  • The method of the present invention may be repeated as necessary until a point is reached, represented by point 615, when the necessary medical procedures are completed. At this point 615, nerve stimulation is off although cardiac stimulation may be left on in order to pace the heart to its normal rhythm. At point 615, the state of cerebral blood circulation may be checked for a final time (as described at 545).
  • It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited, and that numerous other embodiments examples, uses, modifications and departures from the embodiments, examples and uses are intended to be encompassed by the claims attached hereto.

Claims (60)

1-8. (canceled)
9. A method for controlling a heart beat during a medical procedure, comprising:
sensing a first gas level in a body;
stimulating a first nerve to inhibit beating of a heart;
performing at least one step of the medical procedure;
sensing a second gas level while performing the medical procedure;
stopping stimulation of the first nerve to allow beating of the heart when the second gas level is less than the initial gas level.
10. The method of claim 9 wherein the gas level is sensed for at least one of the characteristics selected from the group consisting of presence of oxygen, concentration of oxygen, presence of carbon dioxide, and concentration of carbon dioxide.
11. The method of claim 9 further comprising stimulating the heart with a cardiac stimulator to cause beating of the heart when the second gas level is less than the first gas level.
12. The method of claim 9 wherein the first gas level and second gas level are sensed in cerebral blood flow.
13. The method of claim 9 further comprising providing an alert signal when the second value is less than the first value.
14. The method of claim 12 wherein the alert signal is selected from the group consisting of: a visual signal, a flashing light, an audible signal, and a beeping tone.
15. The method of claim 9 wherein the medical procedure is started after sensing the first gas level, and wherein the second gas level is sensed during the medical procedure.
16. A method for performing a medical procedure, comprising:
sensing a characteristic of a bodily tissue or fluid via a sensor at a first value;
sending a first signal related to the sensed characteristic at a first value;
modifying the beating of a heart via a nerve stimulator in response to the first signal;
performing at least one step of the medical procedure;
sensing the characteristic via the sensor at a second value;
sending a second signal related to the sensed characteristic at a second value; and
modifying the beating of the heart via a cardiac stimulator in response to the second signal.
17. The method of claim 16 wherein modifying the beating of the heart via a nerve stimulator is performed automatically.
18. The method of claim 16 wherein modifying the beating of the heart via a nerve stimulator is performed manually.
19. The method of claim 16 wherein modifying the beating of the heart via a cardiac stimulator is performed automatically.
20. The method of claim 16 wherein modifying the beating of the heart via a cardiac stimulator is performed manually.
21. The method of claim 16 further comprising the delivery of a drug during the medical procedure.
22. The method of claim 21 wherein the drug is delivered via a drug delivery means.
23. The method of claim 22 wherein the drug delivery means is selected from the group consisting of a spray, a cream, an ointment, a medicament, a pill, a patch, a catheter, a cannula, a needle and syringe, a pump, and an iontophoretic drug delivery device.
24. The method of claim 21 wherein the drug is selected from the group consisting of a beta-blocker, a cholinergic agent, a cholinesterase inhibitor, a calcium channel blocker, a sodium channel blocker, a potassium channel agent, adenosine, an adenosine receptor agonist, an adenosine deaminase inhibitor, dipyridamole, a monoamine oxidase inhibitor, digoxin, digitalis, lignocaine, a bradykinin agent, a serotoninergic agonist, an antiarrythmic agent, a cardiac glycoside, a local anesthetic, atropine, a calcium solution, an agent that promotes heart rate, an agent that promotes heart contractions, dopamine, a catecholamine, an inotrope glucagon, a hormone, forskolin, epinephrine, norepinephrine, thyroid hormone, a phosphodiesterase inhibitor, prostacyclin, prostaglandin and a methylxanthine.
25. The method of claim 21 wherein the drug is naturally occurring or chemically synthesized.
26. The method of claim 16 wherein the nerve stimulator modifies the beating of the heart by stimulating a vagal nerve.
27. The method of claim 16 wherein the nerve stimulator modifies the beating of the heart by stimulating a carotid sinus nerve.
28. The method of claim 16 wherein the nerve stimulator modifies the beating of the heart by stimulating a fat pad.
29. The method of claim 16 wherein the bodily fluid is blood.
30. The method of claim 16 wherein the bodily tissue is cardiac tissue.
31. The method of claim 16 wherein the bodily tissue is a nerve.
32. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a chemical characteristic.
33. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a physical characteristic.
34. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a physiological characteristic.
35. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a fluid flow characteristic.
36. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a pressure characteristic.
37. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a temperature characteristic.
38. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is an electrical characteristic.
39. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a chemical concentration.
40. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a protein or peptide.
41. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a component of a metabolic process.
42. The method of claim 16 wherein the characteristic of a bodily tissue or fluid is a gas.
43. The method of claim 42 wherein the gas is oxygen.
44. The method of claim 42 wherein the gas is carbon dioxide.
45. The method of claim 16 wherein the sensor is selected from the group consisting of an imaging system, an electrical sensor, a chemical sensor, an electromagnetic interference sensor, an electrochemical sensor, a pressure sensor, a sound wave sensor, a magnetic sensor, an ultraviolet sensor, a visible light sensor, an infrared sensor, a radiation sensor, a flow sensor, a temperature sensor, a gas sensor, an optical sensor, a pH sensor, a potentiometric sensor, a fluorescence sensor and a biosensor.
46. The method of claim 16 wherein the nerve stimulator comprises one or more electrodes.
47. The method of claim 46 wherein the electrodes are selected from the group consisting of nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, tape-type electrodes, suction-type electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
48. The method of claim 16 wherein the cardiac stimulator comprises one or more electrodes.
49. The method of claim 48 wherein the electrodes are selected from the group consisting of cardiac stimulation electrodes, clip electrodes, needle electrodes, probe electrodes, pacing electrodes, epicardial electrodes, patch electrodes, intravascular electrodes, balloon-type electrodes, basket-type electrodes, tape-type electrodes, umbrella-type electrodes, suction-type electrodes, endotracheal electrodes, endoesophageal electrodes, transcutaneous electrodes, intracutaneous electrodes, screw-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes and cuff electrodes.
50. The method of claim 16 further comprising controlling a patients breathing via a breathing regulator.
51. The method of claim 50 wherein the breathing regulator stimulates a phrenic nerve.
52. The method of claim 50 wherein the breathing regulator controls a respirator.
53. The method of claim 50 wherein the breathing regulator comprises one or more electrodes.
54. The method of claim 53 wherein the electrodes are selected from the group consisting of nerve stimulation electrodes, endotracheal electrodes, endoesophageal electrodes, intravascular electrodes, transcutaneous electrodes, intracutaneous electrodes, balloon-type electrodes, basket-type electrodes, umbrella-type electrodes, suction-type electrodes, screw-type electrodes, tape-type electrodes, barb-type electrodes, bipolar electrodes, monopolar electrodes, metal electrodes, wire electrodes, patch electrodes, cuff electrodes, clip electrodes, needle electrodes and probe electrodes.
55. The method of claim 16 wherein the medical procedure is selected from the group consisting of a surgical procedure, a non-surgical procedure, a fluoroscopic procedure, a cardiac procedure, a vascular procedure, a neurosurgical procedure, an electrophysiology procedure, a diagnostic procedure, a therapeutic procedure, an ablation procedure, an endovascular procedure, a liver procedure, a spleen procedure, a pulmonary procedure, an aneurysm repair, an imaging procedure, a CAT scan procedure, a MRI procedure, a pharmacological therapy, a drug delivery procedure, a biological delivery procedure, a genetic therapy, a cellular therapy, a cancer therapy, a radiation therapy, a transplantation procedure, a coronary angioplasty procedure, a stent delivery procedure, an atherectomy procedure, a procedure that requires precise control of cardiac motion, a procedure that requires precise control of bleeding, a non-invasive procedure, a minimally invasive procedure, an invasive procedure, a port-access procedure, an endoscopic procedure, a sternotomy procedure, a thoracotomy procedure and a robotic procedure.
56. A method for performing a medical procedure, comprising:
sensing a first level of a biological characteristic in a body;
stimulating a nerve to inhibit beating of a heart;
performing at least one step of the medical procedure;
sensing a second level of the biological characteristic while performing the medical procedure;
stopping stimulation of the nerve to allow beating of the heart when the second level differs from the first level by a selective amount.
57. The method of claim 56 wherein the biological characteristic is a chemical characteristic.
58. The method of claim 56 wherein the biological characteristic is a physical characteristic.
59. The method of claim 56 wherein the biological characteristic is a physiological characteristic.
60. The method of claim 56 wherein the biological characteristic is a fluid flow characteristic.
61. The method of claim 56 wherein the biological characteristic is a pressure characteristic.
62. The method of claim 56 wherein the biological characteristic is a temperature characteristic.
63. The method of claim 56 wherein the biological characteristic is an electrical characteristic.
64. The method of claim 56 wherein the biological characteristic is a chemical concentration.
65. The method of claim 56 wherein the biological characteristic is a protein or peptide.
66. The method of claim 56 wherein the biological characteristic is a component of a metabolic process.
67. The method of claim 56 wherein the biological characteristic is a gas.
US11/000,262 2000-09-26 2004-11-30 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure Abandoned US20050096707A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/000,262 US20050096707A1 (en) 2000-09-26 2004-11-30 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66996100A 2000-09-26 2000-09-26
US10/421,459 US6904318B2 (en) 2000-09-26 2003-04-23 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US11/000,262 US20050096707A1 (en) 2000-09-26 2004-11-30 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/421,459 Division US6904318B2 (en) 1996-04-30 2003-04-23 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure

Publications (1)

Publication Number Publication Date
US20050096707A1 true US20050096707A1 (en) 2005-05-05

Family

ID=29420818

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/421,459 Expired - Lifetime US6904318B2 (en) 1996-04-30 2003-04-23 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US11/000,262 Abandoned US20050096707A1 (en) 2000-09-26 2004-11-30 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/421,459 Expired - Lifetime US6904318B2 (en) 1996-04-30 2003-04-23 Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure

Country Status (1)

Country Link
US (2) US6904318B2 (en)

Cited By (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020198570A1 (en) * 1997-08-26 2002-12-26 Puskas John D. Apparatus for indirectly stimulating the vagus nerve with an electrical field
US20040024422A1 (en) * 2000-09-26 2004-02-05 Hill Michael R.S. Method and system for sensing cardiac contractions during a medical procedure
US20040111118A1 (en) * 2000-09-26 2004-06-10 Hill Michael R.S. Method and system for spinal cord stimulation prior to and during a medical procedure
US20040172075A1 (en) * 1996-04-30 2004-09-02 Shafer Lisa L. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US20040186517A1 (en) * 1996-04-30 2004-09-23 Hill Michael R.S. Method and system for nerve stimulation prior to and during a medical procedure
US20040199209A1 (en) * 2003-04-07 2004-10-07 Hill Michael R.S. Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure
US20050061323A1 (en) * 2003-09-18 2005-03-24 Cardiac Pacemakers, Inc. Methods and systems for control of gas therapy
US20050149128A1 (en) * 2003-12-24 2005-07-07 Heil Ronald W.Jr. Barorflex stimulation system to reduce hypertension
US20050149132A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US20050149127A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation responsive to adverse event
US20070142864A1 (en) * 2003-12-24 2007-06-21 Imad Libbus Automatic neural stimulation modulation based on activity
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
US20080140138A1 (en) * 2002-02-26 2008-06-12 Ivanova Svetlana M Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
EP1948300A2 (en) * 2005-10-19 2008-07-30 Northstar Neuroscience, Inc. Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
US20090156921A1 (en) * 2007-12-18 2009-06-18 Huisun Wang Cardiac ablation catheter with oxygen saturation sensor
US7555341B2 (en) 2005-04-05 2009-06-30 Cardiac Pacemakers, Inc. System to treat AV-conducted ventricular tachyarrhythmia
US7840278B1 (en) 1999-06-25 2010-11-23 Puskas John D Devices and methods for vagus nerve stimulation
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US20110082537A1 (en) * 2005-04-11 2011-04-07 Julia Moffitt Transvascular neural stimulation device
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8585648B2 (en) 2010-07-19 2013-11-19 Minipumps, Llc Catheter drug pump
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8660648B2 (en) 2005-10-24 2014-02-25 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US8764708B2 (en) 2006-03-14 2014-07-01 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US20150119793A1 (en) * 2008-08-14 2015-04-30 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US9107995B2 (en) 2008-05-08 2015-08-18 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9199035B2 (en) 2008-05-08 2015-12-01 Minipumps, Llc. Drug-delivery pumps with dynamic, adaptive control
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9271866B2 (en) 2007-12-20 2016-03-01 University Of Southern California Apparatus and methods for delivering therapeutic agents
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9623174B2 (en) 2008-05-08 2017-04-18 Minipumps, Llc Implantable pumps and cannulas therefor
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6006134A (en) 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6904318B2 (en) * 2000-09-26 2005-06-07 Medtronic, Inc. Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US8241274B2 (en) 2000-01-19 2012-08-14 Medtronic, Inc. Method for guiding a medical device
US7706882B2 (en) 2000-01-19 2010-04-27 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area
US8221402B2 (en) 2000-01-19 2012-07-17 Medtronic, Inc. Method for guiding a medical device
US7657312B2 (en) 2003-11-03 2010-02-02 Cardiac Pacemakers, Inc. Multi-site ventricular pacing therapy with parasympathetic stimulation
US7460906B2 (en) 2003-12-24 2008-12-02 Cardiac Pacemakers, Inc. Baroreflex stimulation to treat acute myocardial infarction
US20050278195A1 (en) * 2004-05-28 2005-12-15 Getz Harry L Method for scheduling viewing of a live medical procedure
US7269459B1 (en) * 2005-02-08 2007-09-11 Pacesetter, Inc. Implantable cardiac device with selectable tiered sleep apnea therapies and method
US7613511B2 (en) * 2005-03-09 2009-11-03 Cardiac Pacemakers, Inc. Implantable vagal stimulator for treating cardiac ischemia
US7962208B2 (en) 2005-04-25 2011-06-14 Cardiac Pacemakers, Inc. Method and apparatus for pacing during revascularization
KR100712510B1 (en) 2005-05-09 2007-04-27 삼성전자주식회사 Write strength control method of hard disc drive and recording medium adapted the same
US20080039746A1 (en) 2006-05-25 2008-02-14 Medtronic, Inc. Methods of using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
WO2009081262A1 (en) 2007-12-18 2009-07-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
MX2009010000A (en) 2007-03-19 2010-03-17 Insuline Medical Ltd Drug delivery device.
MX2011004817A (en) 2008-11-07 2011-07-28 Insuline Medical Ltd Device and method for drug delivery.
US9483807B2 (en) * 2009-03-26 2016-11-01 Laguna Mena Inc Hospital communication system
US20110105919A1 (en) * 2009-10-30 2011-05-05 Mohammed Naji Medical device
WO2011150031A1 (en) * 2010-05-25 2011-12-01 Cunningham Miles G Systems and methods for delivering therapeutic agents to selected sites in a subject
US8600505B2 (en) 2011-12-07 2013-12-03 Cyberonics, Inc. Implantable device for facilitating control of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8918191B2 (en) 2011-12-07 2014-12-23 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
US10188856B1 (en) 2011-12-07 2019-01-29 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8577458B1 (en) 2011-12-07 2013-11-05 Cyberonics, Inc. Implantable device for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with leadless heart rate monitoring
US8918190B2 (en) 2011-12-07 2014-12-23 Cyberonics, Inc. Implantable device for evaluating autonomic cardiovascular drive in a patient suffering from chronic cardiac dysfunction
US8630709B2 (en) 2011-12-07 2014-01-14 Cyberonics, Inc. Computer-implemented system and method for selecting therapy profiles of electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction
US8571654B2 (en) 2012-01-17 2013-10-29 Cyberonics, Inc. Vagus nerve neurostimulator with multiple patient-selectable modes for treating chronic cardiac dysfunction
US8700150B2 (en) 2012-01-17 2014-04-15 Cyberonics, Inc. Implantable neurostimulator for providing electrical stimulation of cervical vagus nerves for treatment of chronic cardiac dysfunction with bounded titration
US8688212B2 (en) 2012-07-20 2014-04-01 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing bradycardia through vagus nerve stimulation
US8923964B2 (en) 2012-11-09 2014-12-30 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing heart failure patient awakening through vagus nerve stimulation
US9452290B2 (en) 2012-11-09 2016-09-27 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmia through vagus nerve stimulation
US9643008B2 (en) 2012-11-09 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for enhancing post-exercise recovery through vagus nerve stimulation
US9643011B2 (en) 2013-03-14 2017-05-09 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing tachyarrhythmic risk during sleep through vagus nerve stimulation
US9999773B2 (en) 2013-10-30 2018-06-19 Cyberonics, Inc. Implantable neurostimulator-implemented method utilizing multi-modal stimulation parameters
US9511228B2 (en) 2014-01-14 2016-12-06 Cyberonics, Inc. Implantable neurostimulator-implemented method for managing hypertension through renal denervation and vagus nerve stimulation
US9409024B2 (en) 2014-03-25 2016-08-09 Cyberonics, Inc. Neurostimulation in a neural fulcrum zone for the treatment of chronic cardiac dysfunction
US9415224B2 (en) 2014-04-25 2016-08-16 Cyberonics, Inc. Neurostimulation and recording of physiological response for the treatment of chronic cardiac dysfunction
US9950169B2 (en) 2014-04-25 2018-04-24 Cyberonics, Inc. Dynamic stimulation adjustment for identification of a neural fulcrum
US9713719B2 (en) 2014-04-17 2017-07-25 Cyberonics, Inc. Fine resolution identification of a neural fulcrum for the treatment of chronic cardiac dysfunction
US9272143B2 (en) 2014-05-07 2016-03-01 Cyberonics, Inc. Responsive neurostimulation for the treatment of chronic cardiac dysfunction
US9770599B2 (en) 2014-08-12 2017-09-26 Cyberonics, Inc. Vagus nerve stimulation and subcutaneous defibrillation system
US9737716B2 (en) 2014-08-12 2017-08-22 Cyberonics, Inc. Vagus nerve and carotid baroreceptor stimulation system
US9533153B2 (en) 2014-08-12 2017-01-03 Cyberonics, Inc. Neurostimulation titration process
US9504832B2 (en) 2014-11-12 2016-11-29 Cyberonics, Inc. Neurostimulation titration process via adaptive parametric modification
US10232082B2 (en) 2015-06-29 2019-03-19 480 Biomedical, Inc. Implantable scaffolds for treatment of sinusitis
CA3209217A1 (en) 2015-06-29 2017-01-05 Lyra Therapeutics, Inc. Scaffold loading and delivery systems
EP3313325B1 (en) 2015-06-29 2023-09-06 Lyra Therapeutics, Inc. Implantable scaffolds for treatment of sinusitis
US10973664B2 (en) 2015-12-30 2021-04-13 Lyra Therapeutics, Inc. Scaffold loading and delivery systems
US10201639B2 (en) 2017-05-01 2019-02-12 480 Biomedical, Inc. Drug-eluting medical implants
WO2019195860A2 (en) 2018-04-04 2019-10-10 Vdyne, Llc Devices and methods for anchoring transcatheter heart valve
US11071627B2 (en) 2018-10-18 2021-07-27 Vdyne, Inc. Orthogonally delivered transcatheter heart valve frame for valve in valve prosthesis
US11278437B2 (en) 2018-12-08 2022-03-22 Vdyne, Inc. Compression capable annular frames for side delivery of transcatheter heart valve replacement
US11344413B2 (en) 2018-09-20 2022-05-31 Vdyne, Inc. Transcatheter deliverable prosthetic heart valves and methods of delivery
US10321995B1 (en) 2018-09-20 2019-06-18 Vdyne, Llc Orthogonally delivered transcatheter heart valve replacement
US11109969B2 (en) 2018-10-22 2021-09-07 Vdyne, Inc. Guidewire delivery of transcatheter heart valve
US11253359B2 (en) 2018-12-20 2022-02-22 Vdyne, Inc. Proximal tab for side-delivered transcatheter heart valves and methods of delivery
US11185409B2 (en) 2019-01-26 2021-11-30 Vdyne, Inc. Collapsible inner flow control component for side-delivered transcatheter heart valve prosthesis
US11273032B2 (en) 2019-01-26 2022-03-15 Vdyne, Inc. Collapsible inner flow control component for side-deliverable transcatheter heart valve prosthesis
CN113543750A (en) 2019-03-05 2021-10-22 维迪内股份有限公司 Tricuspid valve regurgitation control apparatus for orthogonal transcatheter heart valve prosthesis
US11076956B2 (en) 2019-03-14 2021-08-03 Vdyne, Inc. Proximal, distal, and anterior anchoring tabs for side-delivered transcatheter mitral valve prosthesis
US11173027B2 (en) 2019-03-14 2021-11-16 Vdyne, Inc. Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
CN114072106A (en) 2019-05-04 2022-02-18 维迪内股份有限公司 Cinching device and method for deploying a laterally delivered prosthetic heart valve in a native annulus
CN114599316A (en) 2019-08-20 2022-06-07 维迪内股份有限公司 Delivery and retrieval devices and methods for sidedly deliverable transcatheter prosthetic valves
WO2021040996A1 (en) 2019-08-26 2021-03-04 Vdyne, Inc. Side-deliverable transcatheter prosthetic valves and methods for delivering and anchoring the same
US11234813B2 (en) 2020-01-17 2022-02-01 Vdyne, Inc. Ventricular stability elements for side-deliverable prosthetic heart valves and methods of delivery

Citations (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3804098A (en) * 1972-04-17 1974-04-16 Medronic Inc Body implantable lead
US3937226A (en) * 1974-07-10 1976-02-10 Medtronic, Inc. Arrhythmia prevention apparatus
US4088140A (en) * 1976-06-18 1978-05-09 Medtronic, Inc. Demand anti-arrhythmia pacemaker
US4088138A (en) * 1974-01-02 1978-05-09 Cardiac Resuscitator Corp. Cardiac resuscitator and monitoring apparatus
US4161952A (en) * 1977-11-01 1979-07-24 Mieczyslaw Mirowski Wound wire catheter cardioverting electrode
US4198963A (en) * 1978-10-19 1980-04-22 Michigan Instruments, Inc. Cardiopulmonary resuscitator, defibrillator and monitor
US4321929A (en) * 1979-10-12 1982-03-30 Lemelson Jerome H Tourniquet
US4332259A (en) * 1979-09-19 1982-06-01 Mccorkle Jr Charles E Intravenous channel cardiac electrode and lead assembly and method
US4458677A (en) * 1979-09-19 1984-07-10 Mccorkle Jr Charles E Intravenous channel cardiac electrode and lead assembly and method
US4574807A (en) * 1984-03-02 1986-03-11 Carl Hewson Method and apparatus for pacing the heart employing external and internal electrodes
US4640298A (en) * 1980-06-03 1987-02-03 Peter Pless Esophageal electrode probe useful for electrical stimulation of the heart
US4671295A (en) * 1985-01-15 1987-06-09 Applied Biometrics, Inc. Method for measuring cardiac output
US4722347A (en) * 1985-01-15 1988-02-02 Applied Biometrics, Inc. Apparatus for measuring cardiac output
US4753244A (en) * 1987-06-23 1988-06-28 Landymore Roderick W Encapsulated microelectronic heart monitor
US4919147A (en) * 1986-10-27 1990-04-24 Josef Reinhardt Esophagus probe
US4929688A (en) * 1988-08-11 1990-05-29 The Goodyear Tire & Rubber Company Cure system for open steam curing of mineral-loaded chlorobutyl compounds
US4928688A (en) * 1989-01-23 1990-05-29 Mieczyslaw Mirowski Method and apparatus for treating hemodynamic disfunction
US4931464A (en) * 1989-02-15 1990-06-05 E. R. Squibb & Sons, Inc. Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
US5003991A (en) * 1987-03-31 1991-04-02 Olympus Optical Co., Ltd. Hyperthermia apparatus
US5007893A (en) * 1988-03-16 1991-04-16 Row Roderick J Combination anti-g and pressure suit
US5014698A (en) * 1987-10-06 1991-05-14 Leonard Bloom Method of and system for monitoring and treating a malfunctioning heart
US5024228A (en) * 1989-11-29 1991-06-18 Goldstone Andrew C Electrode endotracheal tube
US5025807A (en) * 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
US5117822A (en) * 1991-04-05 1992-06-02 Laghi Aldo A Silicone heart spoon
US5117828A (en) * 1989-09-25 1992-06-02 Arzco Medical Electronics, Inc. Expandable esophageal catheter
US5125406A (en) * 1989-11-29 1992-06-30 Eet Limited Partnership (Del) Electrode endotracheal tube
US5127407A (en) * 1989-08-17 1992-07-07 Critikon, Inc. Epidural oxygen sensor
US5178149A (en) * 1989-11-06 1993-01-12 Michael Imburgia Transesophageal probe having simultaneous pacing and echocardiographic capability, and method of diagnosing heart disease using same
US5179952A (en) * 1990-08-13 1993-01-19 Arzco Medical Electronics Inc. Electrocardial stimulator probe
US5179950A (en) * 1989-11-13 1993-01-19 Cyberonics, Inc. Implanted apparatus having micro processor controlled current and voltage sources with reduced voltage levels when not providing stimulation
US5186170A (en) * 1989-11-13 1993-02-16 Cyberonics, Inc. Simultaneous radio frequency and magnetic field microprocessor reset circuit
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5191885A (en) * 1989-02-06 1993-03-09 Arczo Medical Electronics, Inc. Method of terminating an arrhythmia
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5203326A (en) * 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5205285A (en) * 1991-06-14 1993-04-27 Cyberonics, Inc. Voice suppression of vagal stimulation
US5215086A (en) * 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5282468A (en) * 1990-06-07 1994-02-01 Medtronic, Inc. Implantable neural electrode
US5284146A (en) * 1991-06-03 1994-02-08 Applied Biometrics Inc. Removable implanted device
US5292338A (en) * 1992-07-30 1994-03-08 Medtronic, Inc. Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5304220A (en) * 1991-07-03 1994-04-19 Maginot Thomas J Method and apparatus for implanting a graft prosthesis in the body of a patient
US5304206A (en) * 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5306393A (en) * 1992-07-16 1994-04-26 Huyck Licensco, Inc. Method for installing a fabric in a paper machine
US5379765A (en) * 1991-06-12 1995-01-10 Kajiwara; Nagao Monitoring apparatus for use in obtaining bronchial electrocardiogram
US5403356A (en) * 1993-04-28 1995-04-04 Medtronic, Inc. Method and apparatus for prevention of atrial tachy arrhythmias
US5411529A (en) * 1990-08-10 1995-05-02 Medtronic, Inc. Waveform discriminator for cardiac stimulation devices
US5417713A (en) * 1993-02-09 1995-05-23 Leonard Bloom Transesophageal defibrillating system
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5501702A (en) * 1994-06-06 1996-03-26 Medtronic, Inc. Time sharing multipolar rheography apparatus and method
US5507784A (en) * 1993-09-23 1996-04-16 Medtronic, Inc. Method and apparatus for control of A-V interval
US5514161A (en) * 1994-04-05 1996-05-07 Ela Medical S.A. Methods and apparatus for controlling atrial stimulation in a double atrial triple chamber cardiac pacemaker
US5611350A (en) * 1996-02-08 1997-03-18 John; Michael S. Method and apparatus for facilitating recovery of patients in deep coma
US5620468A (en) * 1994-04-21 1997-04-15 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US5713929A (en) * 1996-05-03 1998-02-03 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using ratchet up and decay modes of operation
US5713924A (en) * 1995-06-27 1998-02-03 Medtronic, Inc. Defibrillation threshold reduction system
US5720768A (en) * 1996-05-22 1998-02-24 Sulzer Intermedics Inc. Dual chamber pacing with interchamber delay
US5755682A (en) * 1996-08-13 1998-05-26 Heartstent Corporation Method and apparatus for performing coronary artery bypass surgery
US5874420A (en) * 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5889033A (en) * 1991-02-14 1999-03-30 Mount Sinai School Of Medicine Method and composition for the treatment of apathy-amotivation syndrome
US5893881A (en) * 1995-09-08 1999-04-13 Medtronic, Inc. Method and apparatus for alleviating cardioversion shock pain by delivering a bolus of analgesic
US5893882A (en) * 1996-12-17 1999-04-13 Medtronic, Inc. Method and apparatus for diagnosis and treatment of arrhythmias
US5902324A (en) * 1998-04-28 1999-05-11 Medtronic, Inc. Bi-atrial and/or bi-ventricular sequential cardiac pacing systems
US5913876A (en) * 1996-02-20 1999-06-22 Cardiothoracic Systems, Inc. Method and apparatus for using vagus nerve stimulation in surgery
US5916239A (en) * 1996-03-29 1999-06-29 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US6014588A (en) * 1998-04-07 2000-01-11 Fitz; William R. Facet joint pain relief method and apparatus
US6043273A (en) * 1997-08-08 2000-03-28 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6042538A (en) * 1998-11-18 2000-03-28 Emory University Device for endoscopic vessel harvesting
US6073048A (en) * 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6185459B1 (en) * 1998-08-17 2001-02-06 Medtronic, Inc. Method and apparatus for prevention of atrial tachyarrhythmias
US6221851B1 (en) * 1997-09-19 2001-04-24 Arthur M. Feldman Pharmaceutical therapy for congestive heart failure
US6234985B1 (en) * 1998-06-11 2001-05-22 Cprx Llc Device and method for performing cardiopulmonary resuscitation
US6253108B1 (en) * 1999-04-30 2001-06-26 Intermedics Inc. Method and apparatus for treatment of cardiac electromechanical dissociation
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US6532388B1 (en) * 1996-04-30 2003-03-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6542774B2 (en) * 1996-04-30 2003-04-01 Medtronic, Inc. Method and device for electronically controlling the beating of a heart
US6554781B1 (en) * 1998-12-14 2003-04-29 Spinal Sensor Technologies Limited Spinal monitor apparatus and method
US6572895B2 (en) * 2000-01-18 2003-06-03 Vasogen Ireland Limited Treatment of congestive heart failure
US20040024422A1 (en) * 2000-09-26 2004-02-05 Hill Michael R.S. Method and system for sensing cardiac contractions during a medical procedure
US6690973B2 (en) * 2000-09-26 2004-02-10 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US6711436B1 (en) * 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US20040059383A1 (en) * 1997-08-26 2004-03-25 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US6718208B2 (en) * 1996-04-30 2004-04-06 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US6721603B2 (en) * 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US6735471B2 (en) * 1996-04-30 2004-05-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6738667B2 (en) * 2000-12-28 2004-05-18 Medtronic, Inc. Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
USRE38705E1 (en) * 1996-04-30 2005-02-22 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6904318B2 (en) * 2000-09-26 2005-06-07 Medtronic, Inc. Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US7058447B2 (en) * 2000-09-26 2006-06-06 Medtronic, Inc. Method and system for directing blood flow during a medical procedure

Patent Citations (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3804098A (en) * 1972-04-17 1974-04-16 Medronic Inc Body implantable lead
US4088138A (en) * 1974-01-02 1978-05-09 Cardiac Resuscitator Corp. Cardiac resuscitator and monitoring apparatus
US3937226A (en) * 1974-07-10 1976-02-10 Medtronic, Inc. Arrhythmia prevention apparatus
US4088140A (en) * 1976-06-18 1978-05-09 Medtronic, Inc. Demand anti-arrhythmia pacemaker
US4161952A (en) * 1977-11-01 1979-07-24 Mieczyslaw Mirowski Wound wire catheter cardioverting electrode
US4198963A (en) * 1978-10-19 1980-04-22 Michigan Instruments, Inc. Cardiopulmonary resuscitator, defibrillator and monitor
US4332259A (en) * 1979-09-19 1982-06-01 Mccorkle Jr Charles E Intravenous channel cardiac electrode and lead assembly and method
US4458677A (en) * 1979-09-19 1984-07-10 Mccorkle Jr Charles E Intravenous channel cardiac electrode and lead assembly and method
US4321929A (en) * 1979-10-12 1982-03-30 Lemelson Jerome H Tourniquet
US4640298A (en) * 1980-06-03 1987-02-03 Peter Pless Esophageal electrode probe useful for electrical stimulation of the heart
US5025807A (en) * 1983-09-14 1991-06-25 Jacob Zabara Neurocybernetic prosthesis
US4574807A (en) * 1984-03-02 1986-03-11 Carl Hewson Method and apparatus for pacing the heart employing external and internal electrodes
US4722347A (en) * 1985-01-15 1988-02-02 Applied Biometrics, Inc. Apparatus for measuring cardiac output
US4671295A (en) * 1985-01-15 1987-06-09 Applied Biometrics, Inc. Method for measuring cardiac output
US4919147A (en) * 1986-10-27 1990-04-24 Josef Reinhardt Esophagus probe
US5003991A (en) * 1987-03-31 1991-04-02 Olympus Optical Co., Ltd. Hyperthermia apparatus
US4753244A (en) * 1987-06-23 1988-06-28 Landymore Roderick W Encapsulated microelectronic heart monitor
US5014698A (en) * 1987-10-06 1991-05-14 Leonard Bloom Method of and system for monitoring and treating a malfunctioning heart
US5007893A (en) * 1988-03-16 1991-04-16 Row Roderick J Combination anti-g and pressure suit
US4929688A (en) * 1988-08-11 1990-05-29 The Goodyear Tire & Rubber Company Cure system for open steam curing of mineral-loaded chlorobutyl compounds
US4928688A (en) * 1989-01-23 1990-05-29 Mieczyslaw Mirowski Method and apparatus for treating hemodynamic disfunction
US5191885A (en) * 1989-02-06 1993-03-09 Arczo Medical Electronics, Inc. Method of terminating an arrhythmia
US4931464A (en) * 1989-02-15 1990-06-05 E. R. Squibb & Sons, Inc. Method of reducing pre- and post-ischemic myocardial arrhythmias and fibrillation
US5127407A (en) * 1989-08-17 1992-07-07 Critikon, Inc. Epidural oxygen sensor
US5117828A (en) * 1989-09-25 1992-06-02 Arzco Medical Electronics, Inc. Expandable esophageal catheter
US5178149A (en) * 1989-11-06 1993-01-12 Michael Imburgia Transesophageal probe having simultaneous pacing and echocardiographic capability, and method of diagnosing heart disease using same
US5179950A (en) * 1989-11-13 1993-01-19 Cyberonics, Inc. Implanted apparatus having micro processor controlled current and voltage sources with reduced voltage levels when not providing stimulation
US5186170A (en) * 1989-11-13 1993-02-16 Cyberonics, Inc. Simultaneous radio frequency and magnetic field microprocessor reset circuit
US5024228A (en) * 1989-11-29 1991-06-18 Goldstone Andrew C Electrode endotracheal tube
US5125406A (en) * 1989-11-29 1992-06-30 Eet Limited Partnership (Del) Electrode endotracheal tube
US5282468A (en) * 1990-06-07 1994-02-01 Medtronic, Inc. Implantable neural electrode
US5411529A (en) * 1990-08-10 1995-05-02 Medtronic, Inc. Waveform discriminator for cardiac stimulation devices
US5179952A (en) * 1990-08-13 1993-01-19 Arzco Medical Electronics Inc. Electrocardial stimulator probe
US5188104A (en) * 1991-02-01 1993-02-23 Cyberonics, Inc. Treatment of eating disorders by nerve stimulation
US5889033A (en) * 1991-02-14 1999-03-30 Mount Sinai School Of Medicine Method and composition for the treatment of apathy-amotivation syndrome
US5199428A (en) * 1991-03-22 1993-04-06 Medtronic, Inc. Implantable electrical nerve stimulator/pacemaker with ischemia for decreasing cardiac workload
US5117822A (en) * 1991-04-05 1992-06-02 Laghi Aldo A Silicone heart spoon
US5299569A (en) * 1991-05-03 1994-04-05 Cyberonics, Inc. Treatment of neuropsychiatric disorders by nerve stimulation
US5215086A (en) * 1991-05-03 1993-06-01 Cyberonics, Inc. Therapeutic treatment of migraine symptoms by stimulation
US5284146A (en) * 1991-06-03 1994-02-08 Applied Biometrics Inc. Removable implanted device
US5379765A (en) * 1991-06-12 1995-01-10 Kajiwara; Nagao Monitoring apparatus for use in obtaining bronchial electrocardiogram
US5205285A (en) * 1991-06-14 1993-04-27 Cyberonics, Inc. Voice suppression of vagal stimulation
US5304220A (en) * 1991-07-03 1994-04-19 Maginot Thomas J Method and apparatus for implanting a graft prosthesis in the body of a patient
US5304206A (en) * 1991-11-18 1994-04-19 Cyberonics, Inc. Activation techniques for implantable medical device
US5203326A (en) * 1991-12-18 1993-04-20 Telectronics Pacing Systems, Inc. Antiarrhythmia pacer using antiarrhythmia pacing and autonomic nerve stimulation therapy
US5304120A (en) * 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5306393A (en) * 1992-07-16 1994-04-26 Huyck Licensco, Inc. Method for installing a fabric in a paper machine
US5292338A (en) * 1992-07-30 1994-03-08 Medtronic, Inc. Atrial defibrillator employing transvenous and subcutaneous electrodes and method of use
US5417713A (en) * 1993-02-09 1995-05-23 Leonard Bloom Transesophageal defibrillating system
US5403356A (en) * 1993-04-28 1995-04-04 Medtronic, Inc. Method and apparatus for prevention of atrial tachy arrhythmias
US5507784A (en) * 1993-09-23 1996-04-16 Medtronic, Inc. Method and apparatus for control of A-V interval
US5501703A (en) * 1994-01-24 1996-03-26 Medtronic, Inc. Multichannel apparatus for epidural spinal cord stimulator
US5514161A (en) * 1994-04-05 1996-05-07 Ela Medical S.A. Methods and apparatus for controlling atrial stimulation in a double atrial triple chamber cardiac pacemaker
US5620468A (en) * 1994-04-21 1997-04-15 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US5501702A (en) * 1994-06-06 1996-03-26 Medtronic, Inc. Time sharing multipolar rheography apparatus and method
US5713924A (en) * 1995-06-27 1998-02-03 Medtronic, Inc. Defibrillation threshold reduction system
US5893881A (en) * 1995-09-08 1999-04-13 Medtronic, Inc. Method and apparatus for alleviating cardioversion shock pain by delivering a bolus of analgesic
US5707400A (en) * 1995-09-19 1998-01-13 Cyberonics, Inc. Treating refractory hypertension by nerve stimulation
US6073048A (en) * 1995-11-17 2000-06-06 Medtronic, Inc. Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure
US5874420A (en) * 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
US5611350A (en) * 1996-02-08 1997-03-18 John; Michael S. Method and apparatus for facilitating recovery of patients in deep coma
US5913876A (en) * 1996-02-20 1999-06-22 Cardiothoracic Systems, Inc. Method and apparatus for using vagus nerve stimulation in surgery
US6381499B1 (en) * 1996-02-20 2002-04-30 Cardiothoracic Systems, Inc. Method and apparatus for using vagus nerve stimulation in surgery
US5916239A (en) * 1996-03-29 1999-06-29 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US6718208B2 (en) * 1996-04-30 2004-04-06 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
USRE38705E1 (en) * 1996-04-30 2005-02-22 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US6532388B1 (en) * 1996-04-30 2003-03-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US7184829B2 (en) * 1996-04-30 2007-02-27 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US6735471B2 (en) * 1996-04-30 2004-05-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6912419B2 (en) * 1996-04-30 2005-06-28 Medtronic, Inc. Method and device for electronically controlling the beating of a heart
US6542774B2 (en) * 1996-04-30 2003-04-01 Medtronic, Inc. Method and device for electronically controlling the beating of a heart
US5713929A (en) * 1996-05-03 1998-02-03 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using ratchet up and decay modes of operation
US5720768A (en) * 1996-05-22 1998-02-24 Sulzer Intermedics Inc. Dual chamber pacing with interchamber delay
US5755682A (en) * 1996-08-13 1998-05-26 Heartstent Corporation Method and apparatus for performing coronary artery bypass surgery
US5893882A (en) * 1996-12-17 1999-04-13 Medtronic, Inc. Method and apparatus for diagnosis and treatment of arrhythmias
US6043273A (en) * 1997-08-08 2000-03-28 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6060454A (en) * 1997-08-08 2000-05-09 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6711436B1 (en) * 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US20040059383A1 (en) * 1997-08-26 2004-03-25 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US6221851B1 (en) * 1997-09-19 2001-04-24 Arthur M. Feldman Pharmaceutical therapy for congestive heart failure
US6014588A (en) * 1998-04-07 2000-01-11 Fitz; William R. Facet joint pain relief method and apparatus
US5902324A (en) * 1998-04-28 1999-05-11 Medtronic, Inc. Bi-atrial and/or bi-ventricular sequential cardiac pacing systems
US6234985B1 (en) * 1998-06-11 2001-05-22 Cprx Llc Device and method for performing cardiopulmonary resuscitation
US6185459B1 (en) * 1998-08-17 2001-02-06 Medtronic, Inc. Method and apparatus for prevention of atrial tachyarrhythmias
US6042538A (en) * 1998-11-18 2000-03-28 Emory University Device for endoscopic vessel harvesting
US6554781B1 (en) * 1998-12-14 2003-04-29 Spinal Sensor Technologies Limited Spinal monitor apparatus and method
US6178349B1 (en) * 1999-04-15 2001-01-23 Medtronic, Inc. Drug delivery neural stimulation device for treatment of cardiovascular disorders
US6253108B1 (en) * 1999-04-30 2001-06-26 Intermedics Inc. Method and apparatus for treatment of cardiac electromechanical dissociation
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6572895B2 (en) * 2000-01-18 2003-06-03 Vasogen Ireland Limited Treatment of congestive heart failure
US6904318B2 (en) * 2000-09-26 2005-06-07 Medtronic, Inc. Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US20040024422A1 (en) * 2000-09-26 2004-02-05 Hill Michael R.S. Method and system for sensing cardiac contractions during a medical procedure
US7058447B2 (en) * 2000-09-26 2006-06-06 Medtronic, Inc. Method and system for directing blood flow during a medical procedure
US7184828B2 (en) * 2000-09-26 2007-02-27 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US6690973B2 (en) * 2000-09-26 2004-02-10 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US6738667B2 (en) * 2000-12-28 2004-05-18 Medtronic, Inc. Implantable medical device for treating cardiac mechanical dysfunction by electrical stimulation
US20030045909A1 (en) * 2001-08-31 2003-03-06 Biocontrol Medical Ltd. Selective nerve fiber stimulation for treating heart conditions
US6721603B2 (en) * 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain

Cited By (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040172075A1 (en) * 1996-04-30 2004-09-02 Shafer Lisa L. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US20040186517A1 (en) * 1996-04-30 2004-09-23 Hill Michael R.S. Method and system for nerve stimulation prior to and during a medical procedure
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US20040059383A1 (en) * 1997-08-26 2004-03-25 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US20050143412A1 (en) * 1997-08-26 2005-06-30 Puskas John D. Methods of indirectly stimulating the vagus nerve with an electrical field
US20020198570A1 (en) * 1997-08-26 2002-12-26 Puskas John D. Apparatus for indirectly stimulating the vagus nerve with an electrical field
US7840278B1 (en) 1999-06-25 2010-11-23 Puskas John D Devices and methods for vagus nerve stimulation
US10166395B2 (en) 2000-05-23 2019-01-01 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10561846B2 (en) 2000-05-23 2020-02-18 The Feinstein Institutes For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US9987492B2 (en) 2000-05-23 2018-06-05 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20040111118A1 (en) * 2000-09-26 2004-06-10 Hill Michael R.S. Method and system for spinal cord stimulation prior to and during a medical procedure
US20040024422A1 (en) * 2000-09-26 2004-02-05 Hill Michael R.S. Method and system for sensing cardiac contractions during a medical procedure
US20080140138A1 (en) * 2002-02-26 2008-06-12 Ivanova Svetlana M Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US20040199209A1 (en) * 2003-04-07 2004-10-07 Hill Michael R.S. Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure
US8251061B2 (en) * 2003-09-18 2012-08-28 Cardiac Pacemakers, Inc. Methods and systems for control of gas therapy
US20050061323A1 (en) * 2003-09-18 2005-03-24 Cardiac Pacemakers, Inc. Methods and systems for control of gas therapy
US20110082514A1 (en) * 2003-12-23 2011-04-07 Imad Libbus Hypertension therapy based on activity and circadian rhythm
US8874211B2 (en) 2003-12-23 2014-10-28 Cardiac Pacemakers, Inc. Hypertension therapy based on activity and circadian rhythm
US20050149127A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation responsive to adverse event
US8195289B2 (en) 2003-12-24 2012-06-05 Cardiac Pacemakers, Inc. Baroreflex stimulation system to reduce hypertension
US7783353B2 (en) 2003-12-24 2010-08-24 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity and circadian rhythm
US8639322B2 (en) 2003-12-24 2014-01-28 Cardiac Pacemakers, Inc. System and method for delivering myocardial and autonomic neural stimulation
US7869881B2 (en) 2003-12-24 2011-01-11 Cardiac Pacemakers, Inc. Baroreflex stimulator with integrated pressure sensor
US10342978B2 (en) 2003-12-24 2019-07-09 Cardiac Pacemakers, Inc. Vagus nerve stimulation responsive to a tachycardia precursor
US8626301B2 (en) 2003-12-24 2014-01-07 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US8000793B2 (en) 2003-12-24 2011-08-16 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US8024050B2 (en) 2003-12-24 2011-09-20 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US20070142864A1 (en) * 2003-12-24 2007-06-21 Imad Libbus Automatic neural stimulation modulation based on activity
US8126560B2 (en) 2003-12-24 2012-02-28 Cardiac Pacemakers, Inc. Stimulation lead for stimulating the baroreceptors in the pulmonary artery
US20080228238A1 (en) * 2003-12-24 2008-09-18 Cardiac Pacemakers, Inc. Automatic baroreflex modulation based on cardiac activity
US20050149132A1 (en) * 2003-12-24 2005-07-07 Imad Libbus Automatic baroreflex modulation based on cardiac activity
US10369367B2 (en) 2003-12-24 2019-08-06 Cardiac Pacemakers, Inc. System for providing stimulation pattern to modulate neural activity
US11154716B2 (en) 2003-12-24 2021-10-26 Cardiac Pacemakers, Inc. System for providing stimulation pattern to modulate neural activity
US8285389B2 (en) 2003-12-24 2012-10-09 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on motion and physiological activity
US20050149128A1 (en) * 2003-12-24 2005-07-07 Heil Ronald W.Jr. Barorflex stimulation system to reduce hypertension
US9950170B2 (en) 2003-12-24 2018-04-24 Cardiac Pacemakers, Inc. System for providing stimulation pattern to modulate neural activity
US9561373B2 (en) 2003-12-24 2017-02-07 Cardiac Pacemakers, Inc. System to stimulate a neural target and a heart
US9314635B2 (en) 2003-12-24 2016-04-19 Cardiac Pacemakers, Inc. Automatic baroreflex modulation responsive to adverse event
US8457746B2 (en) 2003-12-24 2013-06-04 Cardiac Pacemakers, Inc. Implantable systems and devices for providing cardiac defibrillation and apnea therapy
US8473076B2 (en) 2003-12-24 2013-06-25 Cardiac Pacemakers, Inc. Lead for stimulating the baroreceptors in the pulmonary artery
US9265948B2 (en) 2003-12-24 2016-02-23 Cardiac Pacemakers, Inc. Automatic neural stimulation modulation based on activity
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US11344724B2 (en) 2004-12-27 2022-05-31 The Feinstein Institutes For Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
US8190257B2 (en) 2005-04-05 2012-05-29 Cardiac Pacemakers, Inc. System to treat AV-conducted ventricular tachyarrhythmia
US20090234408A1 (en) * 2005-04-05 2009-09-17 Julia Moffitt System to treat av-conducted ventricular tachyarrhythmia
US8909337B2 (en) 2005-04-05 2014-12-09 Cardiac Pacemakers, Inc. System to treat AV-conducted ventricular tachyarrhythmia
US7555341B2 (en) 2005-04-05 2009-06-30 Cardiac Pacemakers, Inc. System to treat AV-conducted ventricular tachyarrhythmia
US8929990B2 (en) 2005-04-11 2015-01-06 Cardiac Pacemakers, Inc. Transvascular neural stimulation device and method for treating hypertension
US20110082537A1 (en) * 2005-04-11 2011-04-07 Julia Moffitt Transvascular neural stimulation device
EP1948300A2 (en) * 2005-10-19 2008-07-30 Northstar Neuroscience, Inc. Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
EP1948300A4 (en) * 2005-10-19 2009-03-18 Northstar Neuroscience Inc Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders
US8660648B2 (en) 2005-10-24 2014-02-25 Cardiac Pacemakers, Inc. Implantable and rechargeable neural stimulator
US20070191904A1 (en) * 2006-02-14 2007-08-16 Imad Libbus Expandable stimulation electrode with integrated pressure sensor and methods related thereto
US9693894B2 (en) 2006-03-14 2017-07-04 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US8764708B2 (en) 2006-03-14 2014-07-01 The University Of Southern California MEMS device and method for delivery of therapeutic agents
US8170668B2 (en) 2006-07-14 2012-05-01 Cardiac Pacemakers, Inc. Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090156921A1 (en) * 2007-12-18 2009-06-18 Huisun Wang Cardiac ablation catheter with oxygen saturation sensor
US9308124B2 (en) 2007-12-20 2016-04-12 University Of Southern California Apparatus and methods for delivering therapeutic agents
US9271866B2 (en) 2007-12-20 2016-03-01 University Of Southern California Apparatus and methods for delivering therapeutic agents
US10117774B2 (en) 2007-12-20 2018-11-06 University Of Southern California Apparatus and methods for delivering therapeutic agents
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9107995B2 (en) 2008-05-08 2015-08-18 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9283322B2 (en) 2008-05-08 2016-03-15 Minipumps, Llc Drug-delivery pump with dynamic, adaptive control
US9162024B2 (en) 2008-05-08 2015-10-20 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9623174B2 (en) 2008-05-08 2017-04-18 Minipumps, Llc Implantable pumps and cannulas therefor
US9199035B2 (en) 2008-05-08 2015-12-01 Minipumps, Llc. Drug-delivery pumps with dynamic, adaptive control
US9849238B2 (en) 2008-05-08 2017-12-26 Minipumps, Llc Drug-delivery pump with intelligent control
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US9861525B2 (en) 2008-05-08 2018-01-09 Minipumps, Llc Drug-delivery pumps and methods of manufacture
US9265562B2 (en) * 2008-08-14 2016-02-23 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US20150119793A1 (en) * 2008-08-14 2015-04-30 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US9849286B2 (en) 2009-05-01 2017-12-26 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US10716936B2 (en) 2009-06-09 2020-07-21 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8886339B2 (en) 2009-06-09 2014-11-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US10220203B2 (en) 2009-06-09 2019-03-05 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9700716B2 (en) 2009-06-09 2017-07-11 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9174041B2 (en) 2009-06-09 2015-11-03 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9162064B2 (en) 2009-12-23 2015-10-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8612002B2 (en) 2009-12-23 2013-12-17 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US10384068B2 (en) 2009-12-23 2019-08-20 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8855767B2 (en) 2009-12-23 2014-10-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US9993651B2 (en) 2009-12-23 2018-06-12 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US11110287B2 (en) 2009-12-23 2021-09-07 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US8406868B2 (en) 2010-04-29 2013-03-26 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8423134B2 (en) 2010-04-29 2013-04-16 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US9468764B2 (en) 2010-04-29 2016-10-18 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US10207112B2 (en) 2010-04-29 2019-02-19 Medtronic, Inc. Cardiac therapy including vagal stimulation
US8888699B2 (en) 2010-04-29 2014-11-18 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US11129988B2 (en) 2010-04-29 2021-09-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8585648B2 (en) 2010-07-19 2013-11-19 Minipumps, Llc Catheter drug pump
US9155893B2 (en) 2011-01-19 2015-10-13 Medtronic, Inc. Use of preventative vagal stimulation in treatment of acute myocardial infarction or ischemia
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US9211413B2 (en) 2011-01-19 2015-12-15 Medtronic, Inc. Preventing use of vagal stimulation parameters
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US10449358B2 (en) 2012-03-26 2019-10-22 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11278718B2 (en) 2016-01-13 2022-03-22 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11547852B2 (en) 2016-01-20 2023-01-10 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11383091B2 (en) 2016-01-25 2022-07-12 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11890471B2 (en) 2017-08-14 2024-02-06 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US11857788B2 (en) 2018-09-25 2024-01-02 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation

Also Published As

Publication number Publication date
US20030216790A1 (en) 2003-11-20
US6904318B2 (en) 2005-06-07

Similar Documents

Publication Publication Date Title
US6904318B2 (en) Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US7225019B2 (en) Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US8036741B2 (en) Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6628987B1 (en) Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
US6487446B1 (en) Method and system for spinal cord stimulation prior to and during a medical procedure
US6718208B2 (en) Method and system for nerve stimulation prior to and during a medical procedure
US20070208388A1 (en) Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
EP1324709B1 (en) Medical device for directing blood flow
EP1322382B1 (en) System for endotracheal/esophageal stimulation prior to and during a medical procedure
US6735471B2 (en) Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US20040199209A1 (en) Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure
US7269457B2 (en) Method and system for vagal nerve stimulation with multi-site cardiac pacing
US8162933B2 (en) Vibration sensitive ablation device and method
WO2005053788A1 (en) Method and system for vagal nerve stimulation with multi-site cardiac pacing
US20040267110A1 (en) Method for detection of vulnerable plaque

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION